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1 Introduction 
1.1 Apoptosis in neurodegenerative diseases 
Apoptosis, first described by Kerr et al. in 1972 [1], is morphologically characterized 
by nuclear condensation (pyknosis) and fragmentation, membrane blebbing and 
subsequent formation of apoptotic bodies. The resulting cell fragments, which are 
surrounded by an intact plasma membrane, can be absorbed by other cells via 
phagozytosis. Altogether this provides a ‘silent’ degradation of cells without release 
of cell cytosol which would lead to inflammation and damage of adjacent tissue. In 
contrast, necrotic cell death is associated with rapid cell swelling and rupture of the 
plasma membrane followed by substantial cell damage in the surrounding tissue by 
inflammation [2]. In proliferative tissues, apoptosis is an important mechanism to 
replace old or excessive cells [3]; but also in non proliferating tissues as for example 
brain tissue, apoptotic mechanisms are needed during development of synapses and 
specialized nerve cells [4]. Since this so called programmed cell death occurs all the 
time and almost everywhere in an organism’s life, the pathways involved in apoptosis 
must ensure that dying cells do not adversely affect adjacent cells. While apoptosis is 
a mechanism developed by nature to assure the survival and the function of tissues, 
its dysregulation in neurodegenerative diseases is a major reason for pathological 
neural cell demise, subsequent loss of brain function, and many clinical symptoms in 
patients suffering from acute and chronic neurodegenerative diseases.  
 
In the last years evidence increased that neurodegeneration associated with 
Alzheimer’s disease, Parkinson’s disease, stroke and even brain trauma, but also 
with many other neurodegenerative diseases, is commonly featured by apoptotic 
mechanisms [5]. There are many triggers described for neuronal apoptosis: 
Neurotrophic factor withdrawal [6], activation of glutamate receptors (excitotoxicity) 
[7], oxidative stress (formation of reactive oxygen species ‘ROS’) [8], metabolic stress 
(loss of ATP) [9] and environmental toxins [10]. For example, in acute neurological 
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disorders such as brain trauma and stroke, cell death is caused by glutamate-
mediated excitotoxicity. Ionotropic glutamate receptors such as N-methyl-D-
aspartate- (NMDA) receptors, 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl) 
proprionate (AMPA) receptors or kainate receptors are activated by excessive and 
prolonged extracellular glutamate levels after ischemia or mechanical stimulation of 
these receptors after trauma [11, 12]. This leads to elevated calcium levels in the 
neurons followed by increased ROS production due to mitochondrial dysfunction and 
stimulation of enzymes such as nitric oxide synthase, activation of proteases such as 
calpains and last but not least activation of caspases, the biochemical executors of 
apoptosis. However, it has been shown that both necrosis and apoptosis can occur in 
glutamate-induced excitotoxic cell death in neurons [13]. 
Alzheimer’s disease is a chronic neurodegenerative disease, where accumulation of 
amyloid plaques formed by aggregates of amyloid-β-peptide is associated with the 
death of neurons. Debris of β-amyloid induces apoptosis in a direct way [14] or by 
sensitizing the neurons to oxidative stress and reduced energy availability [7], both 
occurring in brains during ageing. The molecular mechanisms of β-amyloid toxicity 
involves membrane lipid peroxidation, resulting in membrane depolarization through 
impairment of ion transporting ATPases and other membrane transporter proteins. 
Membrane depolarization is followed by calcium influx, ROS production and 
mitochondrial dysfunction and subsequent execution of apoptotic mechanisms [15]. 
The involvement of apoptotic mechanisms has been also demonstrated in neuronal 
cell death that occurs in Parkinson’s disease: Expression and activation of caspases 
seems to be involved in cell death of dopaminergic neurons in the substantia nigra 
and the striatum [16, 17]; furthermore, formation of ROS and mitochondrial 
dysfunction are described as mechanisms involved in neuronal death associated with 
Parkinson’s disease [18]. 
 
All the different acute and chronic neurodegenerative disorders as examplied above 
exhibit different reasons for cell death of neurons. The resulting apoptotic 
mechanisms that play a major role in these disorders follow highly conserved 
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mechanisms although they are induced by many different triggers [19]. Acute brain 
insults such as brain trauma and ischemic stroke are leading causes of death and 
disability in our population and, most notably, chronic neurodegenerative diseases 
are of increasing relevance due to the rising lifespan in our societies. Until now, still 
very few is known about the underlying pathology and efficient treatments for these 
neurodegenerative diseases are not available. Therefore, it is of utmost interest to 
understand mechanisms which are involved in neuronal apoptosis. This is an 
important first step for the development of efficient therapeutic strategies. Therefore, 
a major aim of this thesis was to further elucidate mechanisms of glutamate-induced 
neuronal cell death, a major feature that apparently triggers apoptosis in many 
different neurodegenerative diseases. Immortalized HT-22 neurons were used as a 
glutamate sensitive neuronal cell line. They are derived from mouse hippocampus 
and feature sensitivity to glutamate. From their origin and their glutamate-sensitivity, 
HT-22 neurons act as a representative for neuronal cells. In this model system 
glutamate mediates cell death by glutathione depletion. Glutamate blocks the 
glutamate-cysteine antiporter system Xc- which is important for the cysteine-uptake of 
the cells and therefore limiting for the cells’ glutathione synthesis [20]. Consequently, 
levels of ROS increase within a few hours after glutamate treatment of HT-22 
neurons due to the breakdown of the glutathione pools in the cells. Later, the ROS 
levels further increase in an explosive burst because of the damage of mitochondria 
and the subsequent breakdown of the cellular redox homeostasis. Furthermore an 
elevation of cytosolic calcium levels has been observed following the ROS formation 
in glutamate-exposed HT-22 neurons [21]. Thus, ROS formation, increased calcium 
levels and mitochondrial dysfunction are pre-requisites for the induction of apoptosis 
in this model system similar to the pathological mechanisms that occur in 
neurodegenerative diseases. 
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1.2 Caspases and caspase-independent mechanisms in 
apoptosis 
Activation of caspases is a well established biochemical hallmark of apoptosis [22]. 
Caspases are cysteine proteases with an aspartyl-specificity [23]. Under physiologic 
conditions, they reside in the cytosol as inactive pre-cursors that are activated during 
apoptosis by autoproteolysis, other caspases or other proteases. For example, 
activation of caspases is triggered through death receptor signaling in the so-called 
extrinsic pathway of apoptosis. Complexes of ligand (TNF, Fas-ligand) and 
respective death receptor (p55 or p75, Fas) rapidly activate pro-caspase-1 or pro-
caspase-8, the so-called initiator caspases. 
Pro-caspase-1 or -8 have long pro-domains, such as the death effector domain 
(DED) or the caspase recruitment domain (CARD) which can interact with activating 
proteins containing death domains (DD) or other binding domains. In contrast to the 
initiator caspases, the so-called executing caspases (-3, -6, -7) have shorter pro-
domains with up to now unknown functions [24]. Upon death receptor activation, 
initiator caspases-1, -2, -8 or -10 are cleaved to their active forms. The functional 
initiator caspases then activate the executing caspases-3, -6 and -7 which cleave 
downstream substrates such as, for example, inhibitor of caspase-activated 
deoxyribonuclease (ICAD) [25], inhibitors of apoptosis (IAPs) [26], Rho-associated 
kinase (ROCK) [27], Lamin A [28], or poly(ADP-ribose) polymerase (PARP) [29], 
among others. This caspase-dependent cascade ends up in typical DNA laddering, 
membrane blebbing and forming of apoptotic bodies. For example, the typical DNA 
laddering in apoptotic cells is caused by the activation of caspase-activated 
deoxyribonuclease (CAD) and subsequent DNA fragmentation into 180 bp inter-
nucleosomal DNA fragments or multiples thereof [30, 31]. 
However the extrinsic pathway of the caspase activation cascade can also be 
amplified in an indirect way, involving mitochondrial damage via the so called intrinsic 
pathway [32]. Mitochondrial damage alone is able to initiate the apoptotic pathway 
without death receptor signaling by the release of cytochrome c and subsequent 
activation of caspase-9 [33]. A well known link between the extrinsic and the intrinsic 
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apoptotic pathway is the activation of caspase-8. Besides caspase-3, BH3- 
interacting domain death agonist (Bid), a pro-apoptotic member of the B-cell 
lymphoma-2 (Bcl-2) family, can be cleaved and activated by caspase-8 which results 
in damage of mitochondria, therefore activation of the intrinsic pathway featuring the 
release of cytochrome c from the mitochondrial intermembrane space. Cytochrome c 
forms the apoptosome complex together with apoptosis protease-activating factor-1 
(Apaf-1) and pro-caspase-9 leading to activation of the initiator caspase-9 [34], which 
then cleaves and activates caspase-3 [35]. Further proteins released from 
mitochondria have been identified to promote caspase-dependent apoptosis: For 
example, second mitochondrial derived activator of caspase (Smac/Diablo) and high 
temperature requirement protein A2 (Omi/HtrA2). Both are able to inhibit IAPs 
thereby supporting caspase-dependent apoptosis, either by binding to IAPs (Smac) 
or by cleaving these through serine protease activity (Omi) [36, 37]. Omi/HtrA2 is a 
36-kDa serine protease residing in the mitochondria intermembrane space which can 
be released by different pro-apoptotic stimuli [38] exhibiting its pro-apoptotic function 
by caspase-dependent and even caspase-independent mechanisms [39]. 
Another protein that can execute apoptosis independent of caspases is the apoptosis 
inducing factor (AIF), a 63-kDa flavoprotein, localized to the mitochondria 
intermembrane space [40]. Once released from mitochondria, AIF translocates to the 
nucleus, binds DNA with its pro-apoptotic binding domain [41] and produces large 
scale DNA strand breaks, different from CAD-induced DNA laddering [42]. In 
addition, under physiologic conditions, AIF binds to flavin adenine dinucleotide (FAD) 
and acts as an oxidoreductase [43]. The need of its physiologic expression is 
demonstrated in Harlequin (Hq) mice, in which expression of AIF is reduced to 10-
20%. Hq mice develop ataxia and blindness due to progressive neurodegenerative 
processes in the cerebellum and the retina, respectively. This neurodegeneration is 
linked to higher susceptibility of the neurons to oxidative stress resulting in abnormal 
apoptosis, suggesting that AIF with its oxidoreductase function is an endogenous 
cytoprotector [44]. The name ‘Harlequin mice’ has been imposed due the patchy hair 
loss, which they also develop and which let the mice look like Harlequins. 
1 Introduction  6 
Figure 1: Schematic illustration of human AIF. 
MLS: Mitochondrial localization sequence, NLS Nuclear localization sequence. The DNA binding 
domains residue in the oxidoreductase domain and at the C-terminus 
In this thesis, it was a major aim to examine the involvement of caspase-dependent 
factors, such as caspase-8 and caspase-3, and caspase-independent, pro-apoptotic 
proteins such as AIF in glutamate-induced apoptosis of neuronal cells. For example, 
AIF has been shown in 2003 to be a main mediator of neuronal apoptosis after 
hypoxia-ischemia in neonatal rats [45]. In addition, proteins which induce the 
execution of apoptosis upstream of caspase-3 or AIF were of particular interest. 
Figure 2: Regulation of apoptotic pathways. 
Extrinsic pathway: Death receptors, such as Fas are activated by ligand (FasL) binding, resulting in 
the sequential binding of a Fas associated death domain (DD). Pro-caspase-8, containing the death 
effector domain (DED) in its pro-domain can bind to this complex and becomes activated. Caspase-8 
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either directly activates caspase-3, which leads to the release of CAD (caspase-activated 
deoxyribonuclease) from its inhibitory ligand ICAD and subsequent DNA laddering, or caspase-8 
cleaves the pro-apoptotic protein Bid which activates the intrinsic pathway. Bid cleavage, increased 
ROS- or calcium-levels are capable to induce mitochondrial membrane permeabilization, which leads 
to the release of cytochrome c, Omi/HtrA2, Smac or AIF. Cytochrome c builds a complex with Apaf-1 
and pro-caspase-9 (Apoptosome) which amplifies caspase-3-activation. Omi/HtrA2 and Smac block 
the x-chromosomal linked inhibitor of apoptosis (XIAP), which leads to an indirect activation of 
caspase-3 and 9. AIF is able to execute apoptosis by a caspase-independent way: It translocates to 
the nucleus where it induces large scale (50 kb) DNA fragmentation. Pro-apoptotic Bcl-2-familiy 
members, such as Bid are inhibited by their anti-apoptotic family members, such as Bcl-2. 
 
1.3 Oxidative stress and Mitochondria 
Mitochondria exhibit a crucial role in apoptotic mechanisms. On the one hand they 
are the well known ‘power plants’ of a cell which are responsible for ATP synthesis 
and therefore energy supply. On the other hand, they are a compartment that can 
generate large amounts of reactive oxygen species [46] and the mitochondrial 
intermembrane space harbors different proteins such as cytochrome c, Smac/Diablo, 
Omi/HtrA2, Endonucelase G and AIF, which are capable to mediate programmed cell 
death upon their release into the cytosol [47]. The mitochondrial pathway (intrinsic 
pathway) of apoptosis can amplify cascades of the extrinsic pathway as described 
above. In addition, the intrinsic mitochondrial pathway may be activated by different 
death receptor-independent stimuli as for example ROS, increased calcium levels, 
pro-apoptotic Bcl-2-family members or lipid mediators, such as ceramide [48]. 
For ATP synthesis, electrons are transferred inside the mitochondria from one 
complex of respiratory enzymes to the next and finally to molecular oxygen. Protons 
are translocated across the mitochondrial inner membrane. Thereby the ATP 
synthase gets powered and, as a side effect of the proton gradient, the mitochondrial 
transmembrane potential arises [49]. Since there is a continuous turnover of 
molecular oxygen and electrons, mitochondria are a potential source of huge 
amounts of reactive oxygen species, including superoxide anion radicals, hydroxyl 
radicals, singlet oxygen, hydrogen peroxides and peroxidized nitrogen derivatives. 
Formation and release of ROS are increased after mitochondrial damage and, 
therefore, dysfunctional mitochondria are not only susceptible to oxidative damage, 
but also a source of oxidative stress [46]. Mitochondrial dysfunction by oxidative 
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stress can origin from a disturbance of detoxifying mechanisms as superoxide 
dismutase (SOD), glutathione peroxidase or catalase and results in mitochondrial 
membrane permeabilization and the subsequent breakdown of the mitochondrial  
outer membrane potential. In addition high calcium levels (10-100 µM) can induce 
mitochondrial membrane permeabilization [50]. In neurons, high calcium levels result 
from excitotoxic activation of glutamate receptors. Upon its release from stores in the 
endoplasmatic reticulum (ER), calcium can also link endoplasmatic reticulum stress 
(ER stress) and mitochondrial dysfunction. ER stress results, for example, after 
accumulation of unfolded proteins in the ER, as a consequence of various stimuli, 
including ischemia, lack of trophic support and other neurodegenerative triggers [51]. 
One feature of ER stress is the crosstalk with mitochondria via calcium and 
cytochrome c. Small amounts of cytochrome c from mitochondria can bind to and 
stimulate endoplasmatic reticular IP3-receptors. The subsequent release of calcium 
can trigger the mitochondrial membrane permeabilization, further release of 
cytochrome c from mitochondria and therefore execution of apoptosis [52]. Another 
feature of ER stress is the direct activation of executioner caspases independent of 
mitochondrial involvement: Accumulation of unfolded proteins in the ER leads to the 
activation of chaperones to facilitate protein folding or to suppress mRNA translation 
to block further protein accumulation [53]. In murine cells, ER stress induces the 
activation of caspase-12 which can subsequently activate executioner caspases like 
caspase-3 [54]. Caspase-4 is considered as the human homologue of mouse 
caspase-12 [53, 55]. 
Another regulation pathway of mitochondrial membrane permeabilization is 
represented by the members of the Bcl-2 family [56]. The correlation between 
mitochondrial membrane permeabilization and the breakdown of the mitochondrial 
membrane potential as well as the proteins which are involved in the formation of 
pores for the release of high molecular proteins from mitochondria are controversially 
discussed in the literature. However, there are common features of mitochondrial 
demise during apoptosis of a single cell: Upon induction of apoptosis involving the 
intrinsic pathway, mitochondrial membrane permeabilization occurs with subsequent 
increasing ROS levels, leading to a vicious circle of ROS production and the release 
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of cytochrome c and pro-apoptotic factors, which may activate caspase-dependent or 
caspase-independent pathways and ER stress. In particular, Smac/Diablo or 
Omi/HtrA2 can be released from mitochondria, thereby amplifying the activation of 
caspases. Also caspase-independent proteins, as for example AIF, can be released 
from mitochondria, executing apoptosis by nuclear translocation and DNA cleavage, 
independent from CAD [57]. In this thesis, the pathways of neuronal apoptosis 
downstream of mitochondrial dysfunction were identified. In addition, key players 
upstream of mitochondrial damage and caspase-dependent and caspase-
independent mechanisms were identified in the context of glutamate toxicity in 
neuronal cells. 
1.4 Bcl-2-family proteins 
Multiple evidence demonstrates that the balance of pro- and anti-apoptotic B-cell 
lymphoma-2 (Bcl-2) protein family members is crucial for the regulation of 
mitochondrial integrity and function, thereby sealing a cell’s fate after severe stress 
[58]. The Bcl-2 family consists of two large groups of proteins that either prevent (e.g. 
Bcl-2, Bcl-xl, Bcl-w) or promote apoptosis (e.g. Bax, Bad, Bak, Bid, Bim). These 
proteins can form either homo- or heterodimers and thus either function 
independently or in concert to regulate apoptosis. Bcl-2 and Bcl-xl can form 
heterodimer complexes with Bax to prevent its apoptogenic activity [59]. Upon 
activation, Bad- or Bak-mediated release of Bax from the Bax/Bcl-xl heterodimers or 
by conformational changes after interaction with truncated pro-apoptotic Bid, Bax 
forms a pore in the mitochondrial membrane which allows the release of cytochrome 
c and other pro-apoptotic factors from mitochondria. Bax has been identified as a key 
factor for mitochondrial damage in various models of neuronal apoptosis [58, 60]. In 
contrast to other cells where Bax or Bak can equally mediate mitochondrial damage, 
the prerequisite role of Bax in neuronal apoptosis may be explained by the absence 
of full-length Bak in neurons [61]. 
The translocation of truncated Bid (tBid) to the mitochondria where it interacts with 
Bax [62, 63] has been identified as a major pathway in neuronal cell death triggered 
by death receptor signaling and after cerebral ischemia [64, 65]. The subsequent 
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release of mitochondrial proteins such as cytochrome c or AIF amplifies pathways of 
apoptosis execution downstream of mitochondria. In this thesis, the involvement and 
importance of Bid, as a pro-apoptotic protein upstream of mitochondrial damage, in 
glutamate-induced apoptosis in neuronal cells had to be established. In addition, the 
executors of apoptosis downstream of Bid-mediated apoptosis had to be identified. 
1.5 Activation of Bid in apoptosis 
Bid is the only Bcl-2 family member that can act as a direct agonist of Bax or Bak 
after its activation. It has been shown that cleavage of Bid to tBid is essential for the 
activation of the intrinsic pathway and the subsequent amplification of pro-apoptotic 
mechanisms [60, 62]. For example, Bid-deficient neurons are highly resistant to cell 
death stimuli including oxygen glucose deprivation (OGD) in vitro or cerebral 
ischemia in vivo [65, 66]. Furthermore, Bid knockout mice were protected from 
secondary brain damage after trauma [67]. In sum, various models of 
neurodegeneration with relevance to different neurological diseases, revealed a key 
role for Bid. Usually, inactive full-length Bid resides in the cytosol of healthy cells and 
removing the N-terminal repressor of the C-terminal membrane-anchoring segment 
by proteolytic cleavage is necessary to activate the pro-apoptotic function of Bid [68]. 
The most prominent activator which cleaves Bid to tBid is caspase-8, which itself gets 
activated downstream of stimulated Fas or TNF death receptors. Activation of 
caspase-8 has been shown in primary cultured neurons, after OGD and also in 
rodent brains after an ischemic insult [69, 70] (Figure 3A). Inhibition of both, Fas 
ligand or TNFα protected neurons from apoptosis after OGD. Furthermore, Bid has 
been demonstrated as an ataxia telangiectasia mutated (ATM) effector after DNA 
damage in non-neuronal cells [71, 72]. 
In addition to caspases, other proteases, for example calpains, granzyme B or 
lysosomal hydrolases, can cleave Bid. Activation of calpains depends on elevated 
calcium levels, a common feature of neuronal apoptosis. Calpains cleave different 
substrates, including cytoskeletal proteins, protein kinases and phosphatases, 
membrane receptors and transporter proteins that play important roles in the 
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regulation of cell survival [73, 74]. In addition, calpains can cleave Bid. Calpains 
could therefore amplify pro-apoptotic signaling through mitochondrial damage and 
the subsequent release of pro-apoptotic factors like AIF, cytochrome c or 
Smac/Diablo [58, 75] (Figure 3B). Calpain inhibitors prevented neuronal cell death in 
many different models including, for example, transient forebrain ischemia in rats [76] 
or traumatic brain injury [77], suggesting that calpains play a key role in neuronal cell 
death after acute brain injury [78]. In addition caspase-2 may act as a linker between 
oxidative DNA damage and Bid cleavage [79] (Figure 3D); further, in vitro models of 
hypoxia as well as ischemia models in vivo demonstrated that caspase-1 is capable 
to cleave Bid. Therefore, caspase-1 may mediate mitochondrial damage and 
subsequent execution of cell death after cerebral ischemia [80] (Figure 3C).  
The necessity of Bid cleavage to tBid to activate it’s pro-apoptotic function is recently 
challenged by the finding that translocation of full-length Bid to mitochondria resulted 
in a breakdown of the mitochondrial membrane potential and subsequent nuclear 
condensation in models of glutamate-induced neurotoxicity [81]. In an epithelial cell 
line full-length Bid also mediated apoptosis without previous cleavage by caspase-8 
or interaction with other Bcl-2 family members; in this study, cell death was induced 
by removing the epithelial cells from extracellular matrix and plating them onto 
polyhydroxyethylmethacrylate-coated dishes, which resulted in Bid-dependent 
anoikis [82]. 
Altogether, Bid and its truncated form tBid seem to be central players in the 
mechanisms of apoptotic cell death, in particular in neurons. Therefore, it needs 
further studies to elucidate the exact mechanisms of Bid activation the particular role 
of Bid or tBid in mediating caspase-dependent or caspase-independent apoptosis. In 
this thesis, the involvement of Bid in glutamate-induced apoptosis of neuronal cells 
was addressed, including the mechanisms of Bid activation and downstream 
mechanisms such as mitochondrial damage. 
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Figure 3: Activators of Bcl-2 family member Bid in different models of cell death. 
A. Stimulation of death receptors results in activation of caspase-8, which cleaves Bid and leads to the 
mitochondrial release of cytochrome c B. Bid cleavage is mediated by calpains after increases in 
intracellular calcium levels. C. After cerebral ischemia, activation of caspase-1 via RIP 2 modulator 
and subsequent Bid cleavage occur. This is followed by mitochondrial release of cytochrome c and 
AIF. D. Caspase-2 is activated in response to oxidative DNA damage and activates Bid which leads to 
mitochondrial demise and subsequent processing of caspase-9. 
 
To elucidate the particular role of the different factors in apoptotic processes during 
glutamate-induced neuronal cell death in HT-22 neurons or primary neurons, 
established inhibitors of pro-apoptotic proteins, such as caspase- or calpain-inhibitors 
were applied in the present study as well as novel small molecular Bid inhibitors. 
These Bid inhibitors were developed in the laboratory of Maurizio Pellecchia, The 
Burnham Institute, La Jolla, USA by NMR-based molecular modeling [83]. These 4-
phenyl-sulfanyl-phenylamine-derivatives, as for example BI-6C9 (Figure 4), are the 
first small molecule compounds which exhibited high affinity to pro-apoptotic Bid and 
were able to prevent tBid-induced mitochondrial damage and the subsequent release 
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of pro-apoptotic proteins such as cytochrome c and Smac/Diablo from mitochondria, 
by inhibition of tBid-translocation to mitochondria in non-neuronal cells [83]. These 
inhibitors have not been applied in neurons previously. In addition, small interfering 
RNA (siRNA) applications were established in the neuronal cell model systems to 
allow specific gene silencing of pro-apoptotic factors, in particular when small 
molecule inhibitors were not available. RNA interference was used as a powerful tool 
in neuronal cells to downregulate genes encoding pro-apoptotic proteins, such as Bid 
and AIF, and therefore to examine involvement of these factors in glutamate-induced 
neuronal apoptosis.  
Figure 4: Bid inhibitor BI-6C9. 
 
1.6 Aims of the thesis 
A major aim of this work was to describe the involvement of AIF and thus caspase-
independent mechanisms in glutamate-induced neuronal cell death. In addition, it 
was of interest which proteins and events were involved upstream the release of AIF 
from mitochondria. An understanding of the exact mechanisms, which execute 
apoptosis in neurons after glutamate treatment, may provide important information 
for the development of efficient therapeutic strategies against neurodegenerative 
diseases. 
 
1. It was an aim to describe the role of Bid in glutamate-induced apoptosis of 
neuronal cells. Mechanisms which are involved in the activation of Bid were 
investigated as well as downstream pathways that mediate the execution of 
Bid-dependent apoptosis after glutamate damage in neurons. 
BI-6C9
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2. In order to differentiate between caspase-dependent and caspase-
independent mechanisms downstream of mitochondrial damage during 
glutamate toxicity the particular roles of AIF and caspases were addressed. 
 
3. The findings obtained in the model of glutamate-induced apoptosis in HT-22 
neurons were verified in model systems of primary neurons with relevance to 
stroke, brain trauma and Alzheimer’s disease. 
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2 Materials and methods 
2.1 Chemicals and reagents 
All standard chemicals were obtained from Sigma-Aldrich (Taufkirchen, Germany) 
and Merck (Darmstadt, Germany), if not described otherwise. 
2.1.1 Recombinant proteins 
Human recombinant caspase-8, caspase-1 (ICE) and Omi/HtrA2 (each Merck, 
Darmstadt, Germany) were incubated separately or together for 5-20 minutes at 
37°C with 50 µg protein of HT-22 neuron cell lysate at a final concentration of 100 U / 
40 µl or 1-10 µg / 40 µl, respectively. Volumes were adjusted with 50 mM HEPES 
buffer (Biomol, Hamburg, Germany). 
2.1.2 Caspase substrates 
Fluorogenic substrates of caspase-1 (Z-YVAD-AFC, Merck, Darmstadt, Germany), 
caspase-3 (Ac-DEVD-AMC, Sigma-Aldrich, Taufkirchen, Germany) and caspase-8 
(Ac-IETD-AMC, Sigma-Aldrich, Taufkirchen, Germany) were used for caspase 
activity measurements at final concentrations of 50 µM in 20 µl of HT-22 neuron cell 
lysate. 
2.1.3 Inducers and inhibitors of apoptosis 
Bid inhibitor BI-6C9 (kindly provided by Maurizio Pellecchia, The Burnham Institute, 
La Jolla, California, USA, and from Sigma-Aldrich, Taufkirchen, Germany) was 
dissolved in dimethyl sulfoxide (DMSO) to a stock concentration of 20 mM. It was 
used at a final concentration of 10 µM in Dulbecco’s modified eagle medium (DMEM; 
Biochrom, Berlin, Germany) for HT-22 neurons. Bid inhibitor BI-11A7 (kindly provided 
by Maurizio Pellechia) was dissolved in DMSO to a stock concentration of 20 mM. It 
was used at a final concentration of 2 µM in Earle’s balanced salt solution (EBSS, 
Biochrom, Berlin, Germany) for primary rat neurons. Bax channel blocker (Tocris, 
Ellisville, Missouri, USA) was dissolved in DMSO to a stock concentration of 20 mM 
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and used at final concentration of 0.1-10 µM. Omi/HtrA2 inhibitor UCF-101 (Merck, 
Darmstadt, Germany) was dissolved in DMSO to a stock concentration of 20 mM. It 
was used at final concentrations of 10 µM and 20 µM in DMEM for HT-22 neurons. 
Glutamate (Sigma-Aldrich, Taufkirchen, Germany) was dissolved to a stock 
concentration of 200 mM in EBSS. The pH was adjusted to 7.2 with concentrated 
sodium hydroxide solution (NaOH). It was used at final concentrations from 1 mM to 
5 mM in DMEM for HT-22 neurons and at a final concentration of 20 µM in EBSS for 
primary rat neurons. Staurosporine (STS, Sigma-Aldrich, Taufkirchen, Germany) was 
dissolved in DMSO to a stock concentration of 100 µM. It was used at a final 
concentration of 100-300 nM in DMEM for HT-22 neurons and EBSS for primary rat 
neurons. Caspase-1 inhibitor II (ICE inhibitor, Merck, Darmstadt, Germany) was 
dissolved in DMSO to a stock concentration of 9.24 mM. It was used at final 
concentrations of 1-50 µM in DMEM for HT-22 neurons. Caspase-2 inhibitor I (Z-
VDVAD-FMK, Merck, Darmstadt, Germany) was dissolved in DMSO to a stock 
concentration of 10 mM. It was used at final concentrations of 5-50 µM in DMEM for 
HT-22 neurons. General caspase inhibitor (Z-VAD-FMK, R&D Systems, Wiesbaden, 
Germany) was dissolved in DMSO to a stock concentration of 2 mM. It was used at 
final concentrations of 10-100 µM in DMEM for HT-22 neurons. P38 MAPK inhibitor 
SB 203580 (Tocris, Ellisville, Missouri, USA) was dissolved in DMSO to a stock 
concentration of 20 mM. It was used at final concentrations of 5-20 µM. poly(ADP-
ribose) polymerase (PARP) inhibitor (PJ34, Merck, Darmstadt, Germany) was 
dissolved in aqua dest. to a stock concentration of 20 mM and was used at final 
concentrations of 10 µM. Calpastatin Exon 1B-Derived Peptide was synthesized by 
Genzentrum (München, Germany) and the activated penetratin 1 was purchased 
from Qbiogene (Morgan Irvine, California, USA). The activated penetratin (100 µM in 
H2O) was coupled onto the calpastatin exon 1B-derived peptide (100 µM in H2O) by 
adding an equimolar amount of calpastatin and activated penetratin, and incubated 
for 2 hours at room temperature (RT). The conjugated peptide (50 µM) functioned as 
calpain inhibitor [84] and was used at final concentrations of 0.5 µM to 2 µM. 
Cathepsin inhibitor (E-64-d, Biomol, Hamburg, Germany) was dissolved in DMSO to 
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a stock concentration of 20 mM and was used at final concentrations of 1-50 µM in 
DMEM for HT-22 neurons. 
2.1.4 Transfection reagents 
Opti-MEM I (Invitrogen, Karlsruhe, Germany) was used to form DNA- or siRNA 
transfection complexes. Lipofectamine 2000 (Invitrogen, Karlsruhe, Germany) was 
used at a final concentration of 1.5 µl/ml in antibiotic free DMEM or in antibiotic and 
B27-free Neurobasal medium (NB) to complex DNA plasmids or siRNA. 
2.1.4.1  Plasmid vectors 
The mouse AIF-GFP vector (mAIF_pd2EGFP-N1) was derived from a pd2pEGFP-N1 
vector (Clontech, Palo Alto, California, USA) and an AIF expressing vector 
(pcDNA3.1_mAIF, kind gift of S. Susin, CNRS, Paris, France). The mAIF insert was 
cut out from the pcDNA3.1_mAIF with EcoRI, the stop codon was removed by 
mutagenesis from tga to tCga and then fused to the d2EGFP construct. The resulting 
vector expresses EGFP fused to the C-terminus of mouse AIF that is located in 
mitochondria and allows analysis of AIF-GFP translocation to the nucleus in 
apoptotic cells. The construct was provided by Gerlinde Schwake. ptBid-plasmid was 
generated as described [85]. Plasmids pEGFP-N1 and pEGFP-Luc were purchased 
from Clontech Laboratories (Palo Alto, California, USA). Plasmid pgWIZ-GFP was 
derived from Gene Therapy Systems (San Diego, California, USA) and plasmid 
pCDNA 3.1+ used as a control vector was obtained from Invitrogen (Karlsruhe, 
Germany). The ApoAlert® pDsRed2-Bid Vector which encodes a biologically active 
fluorescent fusion protein of Bid and DsRed monomer was derived from Clontech 
(Palo Alto, California, USA). All the plasmids were amplified using a Quiafilter Giga 
Kit (Quiagen, Hilden, Germany) according to the manufacturer’s protocol. Prior to 
use, their DNA concentrations were determined in a Biophotometer (Eppendorf, 
Hamburg, Germany) and digestion by restriction enzymes with subsequent gel 
electrophoresis analysis was performed. These steps were performed by Melinda 
Kiss. 
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2.1.4.2 siRNA 
AIF-siRNA (5’-AAG AGA AAC AGA GAA GAG CCA-3’), non functional control siRNA 
(mut-siRNA. 5’-AAG AGA AAA AGC GAA GAG CCA-3’) and Parg-siRNA (5’- AAA 
TGG GAC TTT ACA GCT TTG -3’, [86]) were purchased at MWG Biotech 
(Ebersberg, Germany) or AIF and Bid siRNA mixtures were generated using 
recombinant dicer enzyme kit following the instructions of the manufacturer (Gene 
Therapy Systems, San Diego, California, USA). The following steps were performed 
by Miriam Hoehn. An AIF (750bp) or Bid copy DNA (cDNA; 521bp) template for T7-
RNA polymerase in vitro transcription was generated from mouse (for Bid) or rat (for 
AIF) mRNA by reverse transcription polymerase chain reaction [RT-PCR; initial 
denaturation at 95°C for 2 min; 28-30 cycles of 30 s 95°C, 1 min 57°C (AIF) or 60°C 
(Bid), and 2 min 72°C; final extension at 70°C for 10 min] using the following AIF 
primers: forward, 5’-GCG TAA TAC GAC TCA CTA TAG GGA GAT CCA GGC AAC 
TTG TTC CAGC-3’, and reverse, 5’-GCG TAA TACGAC TCA CTA TAG GGA GAC 
CTC TGC TCC AGC CCT ATC G-3’. Following Bid primers were used: forward, 5’-
GCG TAA TAC GAC TCA CTA TAG GGA GAT GGG CTT CTG TCT AAG GAGA-3’, 
and reverse, 5’-GCG TAA TAC GAC TCA CTA TAG GGA GAA GTG AGG CCT TGT 
CTC TGAA-3’. In vitro transcription was performed with the cDNA template by using 
the TurboScript-T7-Transcription kit (Gene Therapy Systems, San Diego, California, 
USA). The resulting double-stranded RNA (dsRNA) template was purified by lithium 
chloride (LiCl) precipitation. Briefly, 30 µl of LiCl solution and 30 µl Nuclease-free 
water were added to the dsRNA template. Mixture was chilled for at least 30 minutes 
at -20°C. Afterwards, it was centrifuged for 15 minutes at maximum speed and 
unincorporated nucleotides were removed by adding 1 ml 70% ethanol. After 
removing the ethanol, the mixture was exposed to the recombinant Dicer enzyme at 
37°C for 16 h overnight, and the siRNA fragments were again purified on the RNA 
Purification Columns 1 (removing salts and unincorporated nucleotides) and 2 
(removing undigested dsRNA) (Gene Therapy Systems, San Diego, California, USA). 
The amount of the purified siRNA was determined in a Biophotometer (Eppendorf, 
Hamburg, Germany) and siRNA was used in concentrations of 10-20 nM. 
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2.1.5 Primary antibodies 
All primary antibodies were diluted in Tris-buffered saline with Tween 20 (TBST). The 
dilution of the Bid-antibody (Cell signaling, Danvers, Massachusetts, USA) was 
1:1,000, of AIF-Antibody (Santa Cruz, Santa Cruz, California, USA) 1:500. α-Tubulin-
antibody (Sigma-Aldrich, Taufkirchen, Germany) was diluted 1:20,000, p38-MAP-
kinase-Antibody (Cellsignaling, Danvers, Massachusetts, USA) was diluted 1:2,000. 
Cleaved-Lamin-A-antibody (Cell signaling, Danvers, Massachusetts, USA) was used 
in a dilution of 1:1,000 and Lamin-A/C-antibody (Cell signaling, Danvers, 
Massachusetts, USA) was used 1:1,000 diluted. 
2.1.6 Secondary antibodies 
All secondary antibodies were purchased from Vector Labs (Burlingame, California, 
USA). Horse reddish peroxidase (HRP) labeled Anti-mouse IgG (H+L), Anti-goat IgG 
(H+L) and Anti-rabbit IgG (H+L) for western blot were used in 1:2,000 - 1:5,000 
dilutions in TBST. The biotinylated Anti-goat IgG (H+L) for immunocytochemistry was 
used in a 1:200 dilution in phosphate-buffered saline (PBS) containing 3% horse-
serum (Invitrogen, Karlsruhe, Germany). 
2.2 Cell biological methods 
Sterile plastic materials for the cell culture were purchased from TPP (T75 flasks, 96-
well plates; Trasadingen, Switzerland), from Nunc (24- and 6-well plates; Wiesbaden, 
Germany) and Becton-Dickinson (35-mm, 60-mm Falcon culture dishes; BD, 
Wiesbaden, Germany). 
2.2.1 Cell culture and induction of apoptosis 
Cell culture media Dulbecco’s modified eagle medium 4.5 g/l glucose (DMEM) and 
Earle’s balanced salt solution (EBSS) were obtained from Biochrom (Berlin, 
Germany). DMEM was supplemented with 10% heat-inactivated fetal calf serum 
(FCS, Invitrogen, Karlsruhe, Germany), 8 ml/l L-alanyl-L-glutamine 200 mM stock 
solution (Biochrom, Berlin, Germany), 5 ml sodium pyruvate 100 mM stock solution 
(Biochrom, Berlin, Germany) and 5 ml Penicillin/Streptomycin 1000 U/ml (Biochrom, 
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Berlin, Germany) for culturing HT-22 neurons. Neurobasal Plus (NB+) contained 500 
ml Neurobasal (Invitrogen, Karlsruhe, Germany) supplemented with 10 ml B27 
supplement (Invitrogen, Karlsruhe, Germany), 1.145 g 4-(2-Hydroxyethyl)piperazine-
1-ethanesulfonic acid (HEPES, Biomol, Hamburg, Germany), 0.176 g L-glutamine 
(Sigma-Aldrich, Taufkirchen, Germany) and 25 mg gentamicin sulfate (Sigma-Aldrich, 
Taufkirchen, Germany) for primary rat neurons. MEM+ was obtained from Eagle’s 
minimum essential medium (Invitrogen, Karlsruhe, Germany) by addition of 1 mM 
HEPES (Biomol, Hamburg, Germany), 26 mM NaHCO3, 40 mM glucose, 20 mM KCl, 
1.2 mM L-glutamine (each Sigma-Aldrich, Taufkirchen, Germany), 1 mM sodium 
pyruvate (Biochrom, Berlin, Germany), 10% (v/v) FCS (Invitrogen, Karlsruhe, 
Germany) and 10 mg/l gentamicin sulfate (Sigma-Aldrich, Taufkirchen, Germany) for 
seeding primary rat hippocampal neurons. Hank’s balanced salt solution (HBSS) was 
made from 100ml 10x HBSS (Invitrogen, Karlsruhe, Germany), aqua dest. (Millipore) 
800 ml, 2.4g HEPES (Biomol, Hamburg, Germany) and 10 mg gentamicin sulfate 
(Sigma-Aldrich, Taufkirchen, Germany). All cells were grown at 37°C in 5% CO2 
humidified atmosphere, provided by a Hera Cell incubator (Kendro Laboratory 
Products GmbH, Hanau, Germany). 
2.2.1.1 HT-22 neurons 
HT-22 neurons were obtained from Gerald Thiel with kind permission by David 
Schubert (Salk Institute, San Diego, California, USA). The HT-22 line was originally 
selected from HT-4 cells based on glutamate sensitivity. HT-4 cells were 
immortalized from primary hippocampal neurons using a temperature-sensitive SV-
40 T antigen [87]. They were cultured in T75 flasks and splitted 1:10 - 1:20 every 3-4 
days. This was performed as follows: Growth medium was replaced by 2 ml PBS 
containing 0.05% trypsin and 0.02% ethylenediaminetetraacetic acid disodium salt 
(EDTA) (1x TE, Invitrogen, Karlsruhe, Germany). Afterwards, cells were incubated 2-
5 min at 37°C. After detaching of the cells, trypsin was inhibited by addition of serum 
containing growth medium. The cells were centrifuged at 179 x g; the cell pellet was 
resuspended in fresh growth medium. Then cells were seeded in 6-well plates with a 
density of 4 x 105 cells / well, in 24-well plates with a density of 8 x 104 / well or in 96-
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well plates with a density of 8 x 103 / well for further treatment. Induction of apoptosis 
was performed 24 h after seeding the cells. Growth medium was removed and 
replaced by medium containing inhibitors of apoptosis. After 1 h preincubation, 
glutamate or STS were added to final concentrations of 1-5 mM or 100-300 nM, 
respectively. Between 0.5 h and 18 h later, cells were analyzed following standard 
procedures for flow cytometry, epifluorescence microscopy, protein or RNA analysis. 
To harvest cells for flow cytometry, epifluorescence microscopy or protein analysis, 
200 µl of 1x TE was used per well for a 24 well plate. 
2.2.1.2 Primary rat neurons 
Embryonic hippocampal cultures: Hippocampi were removed from embryonic day 18 
Sprague-Dawley rats (Charles River Laboratories, Sulzfeld, Germany) and 
dissociated by mild trypsinization and trituration as followed: Isolated hippocampi 
were incubated for 10 min in a solution of 1 mg/ml trypsin (Sigma, Taufkirchen, 
Germany) on Ca2+-and Mg2+-free HBSS. The hippocampi were then rinsed with fresh 
HBSS, exposed for 2 min 1 mg/ml trypsin inhibitor (Sigma, Taufkirchen, Germany), 
and then washed with HBSS. Cells were mechanically dissociated by trituration and 
were then seeded onto 35-mm polyethylenimine-coated culture dishes (for survival 
analysis), 35-mm culture dishes containing glass coverslips (for 
immunocytochemistry), or 60-mm culture dishes (for immunoblot analysis) containing 
1 ml or 2 ml MEM+, respectively. After 4 h incubation, the medium was replaced with 
NB+. Medium was exchanged after 5 days in culture. Since cultures of primary 
neurons develop functional glutamate receptors after 8 days in culture, experimental 
treatments were performed with 9- to 10-day old cultures in EBSS. Apoptosis was 
induced by glutamate (20 µM) in EBSS and quantified 6 - 24 h later. 
2.2.2 Cell viability assays and mitochondrial staining 
For cell viability assays HT-22 neurons were grown in 96-well plates. Primary rat 
hippocampal neurons were grown in 35 mm dishes. For Annexin-V and JC-1 assay, 
HT-22 neurons were cultured in 24-well plates. MitoTracker Green staining was 
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performed in cells cultured on Collagen A-coated Ibitreat µ-slide 8-well plates (Ibidi, 
München, Germany) immediately before confocal microscopic analysis. 
2.2.2.1 MTT-assay 
Metabolic activity of HT-22 neurons was determined by using a 3-(4,5-
Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay in 96-
well plates: To each well 10 µl of a 5 mg/ml MTT solution (Sigma-Aldrich, 
Taufkirchen, Germany) in sterile PBS buffer were added. Cells were incubated at 
37°C for 1.5 h, medium was removed and the samples were frozen at -80°C for at 
least 1 h. Afterwards 100 µl of DMSO were added and samples were incubated at 
37°C for 30 min under constant shaking. Absorbance was measured at 590 nm 
(reference wavelength 630 nm) using a microplate reader (Spectrafluor Plus, Tecan 
Austria GmbH, Grödig, Austria), and cell viability levels were expressed as 
percentage of absorption levels in untreated control cells (100% viability). 
2.2.2.2 DAPI /Hoechst 33342 staining 
Cultured primary neurons were stained in 35 mm-dishes with the fluorescent DNA-
binding dye 4’, 6-diamidino-2-phenylindole dihydrochloride (DAPI) or Hoechst 33342, 
respectively. After removing the medium, cells were fixed in 1 ml of a PBS solution 
containing 4% paraformaldehyde (PFA). Cells were then exposed to 1 µg/ml of the 
respective staining dye in PBS. Cells were washed twice with PBS and kept in 1 ml 
PBS. Stained nuclei were visualized under epifluorescence illumination at an 
excitation wavelength of 365 nm and an emission detected through a 420 nm 
longpass filter (Filter set 02, Carl Zeiss, Jena, Germany) using an Axiovert 200 
microscope (Carl Zeiss, Jena, Germany) with a 20x 0.40 NA objective (Carl Zeiss, 
Jena, Germany). Neurons with condensed and fragmented nuclei were considered 
apoptotic, whereas healthy neurons exhibited low staining intensity and the staining 
was evenly distributed over the nuclei. 
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2.2.2.3 Annexin-V-FITC staining 
Apoptotic cells were detected after labeling with annexin-V and subsequent flow 
cytometry. Annexin-V binds in the presence of calcium to phosphatidylserine, which 
appears on the cell surface in early phases of apoptosis [88]. HT-22 neurons were 
harvested 17-20 h after glutamate- or STS-treatment by using trypsin/EDTA, washed 
once in PBS and resuspended in 1x annexin-V binding buffer (Sigma-Aldrich, 
Taufkirchen, Germany) at a concentration of approximately 1.6 x 105 cells / 500 µl. 
The DNA stain propidium iodide (PI, Sigma-Aldrich, Taufkirchen, Germany) and 
annexin V-FITC (Sigma-Aldrich, Taufkirchen, Germany) were added at 1 µg/ml each 
and incubated for 10 min at RT. Apoptotic and necrotic cells were determined using a 
CyanTM MLE flow cytometer (DakoCytomation, Copenhagen, Denmark). Annexin V-
FITC fluorescence was excited at a wavelength of 488 nm and emission was 
detected using a 530±40 nm bandpass filter. Propidium iodide fluorescence was 
excited at a wavelength of 488 nm and emission was detected using a 680±30 nm 
bandpass filter. To exclude cell debris and doublets, cells were appropriately gated 
by forward versus side scatter and pulse width, and 1 x 104 gated events per sample 
were collected. Cells which are at an early stage of apoptosis were stained with 
annexin-V alone. Living cells did not show any staining. Necrotic cells were stained 
by both, annexin-V and propidium iodide. 
2.2.2.4 JC-1-assay (Mitochondrial function) 
Mitochondrial membrane potential of HT-22 neurons was determined by 5, 5', 6, 6'-
tetrachloro-1, 1', 3, 3'-tetraethylbenzimidazolylcarbocyanine iodide (JC-1) reduction. 
HT-22 neurons were stained with JC-1 (Mitoprobe, Invitrogen, Karlsruhe, Germany) 
according to the manufacturer’s protocol and analyzed by subsequent flow cytometry 
or epifluorescence microscopy. After glutamate treatment (6-12 hours), JC-1 was 
added to each well of each condition at a final concentration of 2 µM. Living-control 
cells were left untreated and damage-control cells were treated with carbonyl cyanide 
m-chlorophenylhydrazone (CCCP) 5 minutes before staining to induce mitochondrial 
membrane depolarization. Supernatants of each condition were collected (to avoid 
the loss of detached cells) and cells harvested using 1x TE. After detaching of the 
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HT-22 neurons TE reaction was stopped by adding 800 µl serum-containing medium 
to each well. Cells were resuspended and transferred to their respective supernatant. 
Cells were centrifuged at 179 x g, supernatants were removed, pellet washed once in 
PBS, resuspended in 700 µl PBS and kept on ice. Mitochondrial membrane potential 
was determined using a CyanTM MLE flow cytometer (DakoCytomation, 
Copenhagen, Denmark). JC-1 green fluorescence was excited at 488 nm and 
emission was detected using a 530±40 nm bandpass filter. JC-1 red fluorescence 
was excited at 488 nm and emission was detected using a 613±20 nm bandpass 
filter. To exclude cell debris and doublets, cells were appropriately gated by forward 
versus side scatter and pulse width, and 1 x 104 gated events per sample were 
collected. All mitochondria get loaded by JC-1 dye which leads to a green 
fluorescence. Living cells with intact mitochondria are able to reduce JC-1 and 
produce an additional red fluorescence. 
2.2.2.5 MitoTracker Green staining (Mitochondrial visualization) 
To 50 µg MitoTracker Green (Invitrogen, Karlsruhe, Germany) 74.4 µl DMSO were 
added. The resulting 1 mM solution was diluted 1:10,000 in DMEM and 300 µl were 
added to HT-22 neurons after their respective treatment in Collagen A-coated Ibitreat 
µ-slide 8 well plates. Cells were incubated for 15 minutes at 37°C with the staining 
medium. Afterwards, the staining medium was replaced with DMEM and 
mitochondria were visualized using a confocal laser scanning microscope at an 
excitation wavelength of 488 nm (Carl Zeiss, Jena, Germany). Light was collected 
through a 100 x 1.3 NA oil immersion objective. MitoTracker Green fluorescence was 
excited at a wavelength of 488 nm and emission was detected using a 560 nm 
longpass filter. 
2.2.3 Transmission light and epifluorescence microscopy 
Transmission light microscopy of living HT-22 neurons was performed using an 
Axiovert 200 microscope (Carl Zeiss, Jena, Germany) equipped with a Sony DSC-
S75 digital camera (Sony Corporation, Tokyo, Japan). Light was collected through 5 
x 0.12 NA. 10 x 0.25 NA or 32 x 0.40 NA objectives (Carl Zeiss, Jena, Germany), and 
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images were captured using phase contrast. Imaging of JC-1-stained HT-22 neurons 
or DAPI-stained primary rat hippocampal neurons was performed using an Axiovert 
200 fluorescence microscope, equipped with a Zeiss Axiocam camera (Carl Zeiss, 
Jena, Germany). JC-1 green fluorescence was excited using a 470±20 nm bandpass 
filter, and emission was collected using a 540±25 nm bandpass filter (Filter set 10, 
Carl Zeiss, Jena, Germany). JC-1 red fluorescence was excited using a 557.5±27.5 
nm bandpass filter, and fluorescence emission was collected using a 615 nm 
longpass filter (Filter set 00, Carl Zeiss, Jena, Germany). DAPI fluorescence was 
excited using a G 365 nm bandpass filter, and emission was collected using a 420 
nm longpass filter (Filter set 02, Carl Zeiss, Jena, Germany). For digital imaging the 
software LSM 510 3.20 SP2 (Carl Zeiss, Jena, Germany) was used. 
2.2.4 Transfection protocols 
HT-22 neurons were transfected in 24 well plates, 24 hours after seeding at a density 
of 8 x 104 cells per well. Antibiotic containing growth medium was replaced by 900 µl 
antibiotic free DMEM per well. Six days old primary rat hippocampal neurons were 
transfected in 35 mm culture dishes at a density of 3.5 x 105 cells per dish. NB+ was 
replaced by 900µl NB without B27 supplement and antibiotics. 
2.2.4.1 DNA-transfections 
Lipofectamine 2000 (Invitrogen, Karlsruhe, Germany) and the respective DNA 
plasmids were dissolved separately in Opti-MEM I (Invitrogen, Karlsruhe, Germany). 
After 10 min of equilibration at room temperature each DNA solution was combined 
with the respective volume of the Lipofectamine solution, mixed gently, and allowed 
to form plasmid liposomes for further 20 min at room temperature. The transfection 
mixture was added to the antibiotic-free cell culture medium to a final concentration 
of 1 µg DNA and 1.5 µl/ml Lipofectamine 2000 in HT-22 neurons. Controls were 
treated with 100 µl/ml Opti-MEM I only, and vehicle controls with 1.5 µl/ml 
Lipofectamine 2000. Cells were transfected for at least 24 h, before further treatment. 
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2.2.4.2 Flow cytometric analysis of DNA transfection efficiency in HT-22 neurons 
To determine transfection efficiency, HT-22 were transfected with different EGFP-
encoding plasmids, i.e. pEGFP-N1, pEGFP-Luc and pgWIZ-GFP, followed by 
analysis of the relative percent of transfected to non-transfected cells. Twenty-four 
hours after transfection with the plasmids, cells were harvested after 1x TE-exposure 
and kept on ice. The number of EGFP-positive cells was quantified using a Cyan 
MLE flow cytometer (DakoCytomation, Copenhagen, Denmark). Fluorescence of 
EGFP was excited at a wavelength of 488 nm and emission was detected using a 
530±40 nm bandpass filter. To exclude cell debris and doublets, cells were 
appropriately gated by forward versus side scatter and pulse width, and 1 x 104 gated 
events per sample were collected. 
2.2.4.3 siRNA-transfections 
For siRNA transfections, Lipofectamine 2000 (Invitrogen, Karlsruhe, Germany) and 
AIF-siRNA, Bid-siRNA, Parg-siRNA, or non-functional mut-siRNA were dissolved 
separately in Opti-MEM I (Invitrogen, Karlsruhe, Germany). After 10 min of 
equilibration at RT, each siRNA solution was combined with the respective volume of 
the Lipofectamine 2000 solution, mixed gently, and allowed to form siRNA liposome 
complexes for further 20 min at room temperature. The transfection mixture was 
added to the antibiotic-free cell culture medium to a final concentration of 10-20 nM 
(dicer products) and up to 80 nM siRNA (single siRNA sequences), and 1.5 µl/ml or 
2µl/mL Lipofectamine in HT-22 neurons. Controls were treated with 100 µl/ml Opti-
MEM I only, and vehicle controls with 1.5-2 µl/ml Lipofectamine 2000. 
2.2.5 Immunocytochemistry and confocal laser scanning microscopy (CLSM) 
For immunocytochemistry primary rat hippocampal neurons cultured on PEI-coated 
35 mm culture dishes containing glasscoverslips were fixed with 4% PFA after their 
respective treatment. Culture medium was removed and cells were washed once with 
PBS. Afterwards, cells were fixed in 1 ml 4% paraformaldehyde for 20 minutes, 
washed 1x in PBS and then membranes were permeabilized by exposure for 5 min 
to 0.4% Triton X-100 (Sigma-Aldrich, Taufkirchen, Germany) in PBS, and cells were 
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placed in blocking solution [3% horse serum (Invitrogen, Karlsruhe, Germany) in 
PBS] for 30 min. Cells were then exposed to a polyclonal anti-AIF antibody (1:100 in 
block solution, Santa Cruz Biotechnology, Santa Cruz, California, USA), overnight at 
4°C and subsequent 2.5 h at room temperature, followed by an incubation for 1 h 
with biotinylated anti-goat IgG antibody (1:200, Vector Labs, Burlingame, CA. USA) 
and 30 minutes in the presence of streptavidin oregon green 514 conjugate 
(Invitrogen, Karlsruhe, Germany) according to the manufacturers protocol. The 
specificity of AIF immunoreactivity was controlled by omission of the primary 
antibody. Nuclei were counterstained with DAPI as described above. Images were 
acquired using a confocal laser scanning microscope (LSM 510, Carl Zeiss, Jena, 
Germany) equipped with an UV and an argon laser delivering light at 364 nm and 
488 nm, respectively. Light was collected through a 63 x 1.4 NA oil immersion 
objective. DAPI fluorescence was excited at 364 nm and emission was achieved by 
using the 385 nm longpass filter. Fluorescence of oregon green was excited at a 
wavelength of 488 nm and emission was detected using a 505 nm longpass filter. For 
digital imaging, the software LSM 510 3.20 SP2 (Carl Zeiss, Jena, Germany) was 
used. 
2.2.6 Confocal laser scanning microscopy of HT-22 neurons 
For detection of AIF or Bid localization during apoptosis, HT-22 neurons were 
transfected with the mAIF_pd2EGFP-N1 or the pDsRed2-Bid plasmid, respectively. 
Twenty four hours after transfection HT-22 neurons were seeded in collagen A-
coated Ibitreat µ-slide 8-well plates (Ibidi, München, Germany) at a density of 1 x 104 
/ well for endpoint analysis or, for time lapse pictures in a microscope-attached CO2-
chamber at the LSM 510, Zeiss, Germany) onto a round glasscoverslip (H. Saur, 
Reutlingen, Germany) with a diameter of 42 mm and a thickness of 0.17 mm. 
Mitochondria were stained with MitoTracker Green (Invitrogen, Karlsruhe, Germany) 
as described above. Endpoint pictures were taken after fixation with 4% PFA and 
DAPI counterstaining of the nuclei between 5 h to 17 h after onset of treatment. 
Images were acquired using a confocal laser scanning microscope (LSM 510, Carl 
Zeiss, Jena, Germany) equipped with an UV, an argon and a Helium/Neon laser, 
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delivering light at 364 nm, 488 nm and 543 nm respectively. Light was collected 
through a 40 x 1.3 NA, 63 x 1.4 NA or 100 x 1.3 NA oil immersion objectives. DAPI 
fluorescence was excited at 364 nm and emission was achieved by using the 385 nm 
longpass filter. Fluorescences of MitoTracker Green or AIF-GFP and DsRed were 
excited at 488 nm and 543 nm and emissions were observed using 505-530 nm 
bandpass (green) and 560 nm longpass filters (red), respectively. For real time 
confocal microscopy the CO2-chamber was adjusted to 37°C, 5% CO2 and a 
humidified atmosphere. Images were acquired every five minutes up to 17 hours 
after onset of treatments with the same laser settings as for ‘endpoint pictures’.  They 
were exported to a movie file, using the software LSM 510 3.20 SP2 (Carl Zeiss, 
Jena, Germany). 
2.3 Protein analysis 
For protein extraction and subsequent analysis, HT-22 neurons were grown at a 
density of 8 x 104 cells per well in 24-well plates (western blot) or 4 x 105 cells per 
well in 6-well plates (caspase activity assays). Primary rat neurons were cultured in 
PEI-coated 60 mm culture dishes at 1 density of 1.5 x 106 cells per dish. 
2.3.1 Protein sample preparation from HT-22 neurons and from primary rat 
neurons 
For western blot analysis, HT-22 neurons were harvested as described using 1x TE 
solution to detach cells. At least 4 wells per condition were pooled. Cells were 
washed in PBS and lysed with 50-150 µl 1:5 diluted cell lysis reagent 5x (Promega, 
Mannheim, Germany), supplemented with 1 tablet /10 ml Complete Mini protease 
inhibitor cocktail (Roche, Mannheim, Germany), containing a cocktail of several 
reversible and irreversible protease inhibitors. Protein extracts were kept on ice for 
15 minutes and then extracts were centrifuged at 15,000 x g for 15 minutes at 4°C to 
remove insoluble membrane fragments. The supernatants were stored at -80°C until 
further use. For nuclear and cytosolic protein extracts, HT-22 neurons were 
harvested using 1x TE solution. The resulting cell pellets were fractionated using the 
Nuclear Extract Kit (Active Motif, Rixensart, Belgium) according to the manufacturer’s 
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instructions. Briefly, the pellet was dissolved in hypotonic buffer and incubated for 15 
minutes on ice. The suspension was centrifuged at 15,000 x g at 4°C. Supernatant 
(cytosolic extract) was stored at -80°C. The pellet containing the nuclei was 
incubated in lysis buffer (Active Motif, Rixensart, Belgium) and stored at -80°C. For 
caspase activity assays, 6-well plates were put on ice and incubated for 15 min. 
Medium was removed and cells were washed once with 3 ml ice cold PBS. 150 µl 
lysis buffer (5 mM MgCl2, 1 mM EGTA, 0.1% Triton X-100, 25 mM HEPES in 50 ml 
aqua dest.) were added to the first well. Cells were harvested using a cell scraper 
(Sarstedt, Newton, North Carolina, USA). The lysate was then transfered into the 
next well of the same condition and cells were scraped. At least 3 wells of each 
condition were pooled. Lysates were transferred to an Eppendorf tube and 
homogenated by 10 strokes through a 20-gauge needle. Insoluble membrane 
fragments were separated by centrifuging at 15,000 x g for 15 minutes at 4°C. Pellets 
were discarded, and supernatants were stored at -80°C. 
To achieve full protein extract of primary rat neurons, cells were scraped as 
described above for HT-22 in PBS containing 1 tablet Complete Mini protease 
inhibitor cocktail (Roche, Mannheim, Germany) per 10 ml and centrifuged at 64 x g 
for 15 min at 4°C. The pellet was washed once in PBS and was resuspended in 50-
150 µl cell lysis reagent (Promega, Mannheim, Germany), supplemented with 
Complete Mini protease inhibitor cocktail (Roche, Mannheim, Germany). Protein 
extracts were kept on ice for 15 minutes. To remove insoluble membrane fragments, 
extracts were centrifuged at 15,000 x g for 15 minutes at 4°C and supernatants were 
stored at -80°C. 
2.3.2 Determination of protein amount 
Protein amounts in extracts were determined with the Pierce BCA kit (Perbio 
Science, Bonn, Germany). To this end, 5 µl of each sample were diluted in 95 µl 
PBS. A standard curve containing 0-100 µg bovine serum albumin (Perbio science, 
Bonn, Germany) per 100 µl, 5 µl of the respective lysis buffer and PBS ad 100 µl was 
prepared. Then, 500 µl of a 1 : 50 mixture of reagent B : reagent A (Perbio Science, 
Bonn, Germany) was added to each sample. Samples were incubated for 30 minutes 
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at 60°C; 150 µl of each sample were pipetted into a 96-well plate (Nunc, Wiesbaden, 
Germany). Absorption at 590 nm was determined using a SpectrafluorPlus plate 
reader (Tecan, Grödig, Austria) and protein amounts of the test samples were 
calculated from the standard curve. 
2.3.3 Polyacrylamid gel electrophoresis and western blot 
For gel electrophoresis and western blot analysis, the following solutions were used: 
0.5 M Tris [7.88 g Tris-HCl (Sigma-Aldrich, Taufkirchen, Germany) in 100 ml Millipore 
water, adjusted to pH 6.8 by concentrated HCl], 1.5 M Tris [23.6 g Tris-HCl (Sigma-
Aldrich, Taufkirchen, Germany) in 100 ml Millipore water, adjusted to pH 8.8 by 
concentrated HCl], 10% APS [Ammoniumpersulfat (Sigma-Aldrich, Taufkirchen, 
Germany) 1 g in 10 ml Millipore water], N,N,N′,N′-Tetramethylethylenediamine 
(TEMED, Promega, Mannheim, Germany), sodium dodecyl sulfate 10% (SDS, Roth, 
Karlsruhe, Germany) 10 g in 100 ml Millipore water], electrophoresis buffer [3.0 g 
trizma base (Sigma-Aldrich, Taufkirchen, Germany), 14.4 g glycine (Roth, Karlsruhe, 
Germany) and 1 g SDS (Roth, Karlsruhe, Germany) in 1000 ml Millipore water], 
transfer buffer [3.0 g trizma base (Sigma-Aldrich, Taufkirchen, Germany), 14.4 g 
glycine (Roth, Karlsruhe, Germany), 100 ml methanol p.a. ad 1000 ml Millipore 
water], TBST [2.42 g trizma base (Sigma-Aldrich, Taufkirchen, Germany), 29.2 g 
sodium chloride (Sigma-Aldrich, Taufkirchen, Germany), 0.5 ml Tween 20 (Roth, 
Karlsruhe, Germany) ad 1000 ml Millipore water], loading buffer [7 ml 1M Tris-HCl pH 
6,8, 3 ml glycerol (Sigma-Aldrich, Taufkirchen, Germany), 1 g SDS (Roth, Karlsruhe, 
Germany), 0.93 g DTT (D,L-dithiotreitol, Sigma-Aldrich, Taufkirchen, Germany), 100 
µl β-mercaptoethanol (Merck, Darmstadt, Germany), 1.2 mg bromophenol blue 
sodium salt (Sigma-Aldrich, Taufkirchen, Germany), 5 g blocking buffer [non-fatty 
milk powder (Töpfer, Dietmannsried, Germany) in 100 ml TBST] and strip buffer [3.84 
g trizma base (Sigma-Aldrich, Taufkirchen, Germany), 10.0 g SDS (Roth, Karlsruhe, 
Germany) in 500 ml Millipore water, adjusted to pH 6.7 by concentrated HCl; β-
mercaptoethanol (Merck, Darmstadt, Germany) was added immediately before use 
(78 µl in 10 ml strip buffer]. Discontinuous polyacrylamid gels (resolving gel 10% or 
15% polyacrylamid, stacking gel 3.5% polyacrylamid) were cast using the Mini-
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Protean 3 cell with 1.5 mm spacer and 10-pocket combs (Bio-RAD, München, 
Germany). Resolving gels contained following components: 2.5 ml 1.5 M Tris, 0.1 ml 
SDS 10%, 3.34 ml (10%) or 5 ml (15%) 30% Acrylamid/Bis solution 29:1 (Bio-Rad, 
München, Germany), 0.05 ml 10% APS, 0.01 ml TEMED and Millipore water ad 10 
ml. Stacking gels were prepared with 2.5 ml 0.5 M Tris, 0.1 ml SDS 10%, 1.2 ml 
(3.5%) 30% Acrylamid/Bis solution 29:1 (Bio-Rad, München, Germany), 0.05 ml 10% 
APS, 0.01 ml TEMED and Millipore water ad 10 ml. An amount of 50 µg protein of 
each sample was filled up to 40 µl with RNase-free water (Sigma-Aldrich, 
Taufkirchen, Germany). 8 µl loading buffer were added and boilt at 95°C for 5 
minutes. Then samples were loaded onto the gel and 10 µl of Precision Plus Protein 
Dual Color Standard (Bio-Rad, München, Germany) were used on each gel as 
molecular weight marker. The electrophoresis was performed at 100 V for 20 minutes 
and subsequent 60 mA for 1 h per 2 gels in electrophoresis buffer. After 
electrophoresis, proteins were blotted onto a porablot polyvinylidenfluorid membrane 
(PVDF , Macherey und Nagel, Düren, Germany) according to the Bio-Rad protocol at 
15-20 V for 45 minutes. Blotting was performed in a Trans-Blot SD semi-dry transfer 
cell (Bio-Rad, München, Germany) using extra thick filter paper (Bio-Rad, München, 
Germany) and transfer buffer. Membranes were dried at 37°C for 1 h, before 
incubating in 8 ml blocking buffer + 36 µl Tween 20 (Sigma-Aldrich, Taufkirchen, 
Germany). Then blots were probed with an appropriate primary antibody in block 
solution at 4°C overnight; afterwards, membranes were washed and then exposed to 
a HRP-conjugated secondary antibody. Binding was detected by chemiluminescence 
using ECL (Visualizer Spray & Glow, Chemicon & Upstate, Hampshire, United 
Kingdom) and CL-X Posure Films 8 x 10 inches (Perbio Sciences, Bonn, Germany). 
Equal protein loading was controlled by re-probing the membrane with the 
monoclonal anti-α-tubulin antibody (Sigma-Aldrich, Taufkirchen, Germany) and the 
respective secondary antibody. 
2.3.4 Caspase-activity assay 
Triplicates of each sample (20 µl) were added to a black 96-well plate with flat and 
transparent bottom (Nunc, Wiesbaden, Germany) and incubated with 90 µl freshly 
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prepared substrate solution [37.5 µl DTT 16% solution and 16.9 µl of 10 mM 
caspase-3-substrate-solution Ac-DEVD-AMC (Sigma-Aldrich, Taufkirchen, 
Germany), capase-8-substrate solution Ac-IETD-AMC (Sigma-Aldrich, Taufkirchen, 
Germany) or caspase-1-substrate Z-YVAD-AFC (Merck, Darmstadt, Germany) added 
to 3 ml Buffer B (5.96 g HEPES, 5.0 g Sucrose, 0.5 g 3-[(3-
Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), aqua dest. ad 
500.0 ml, pH 7.5)]. After 5 min of incubation, fluorescence (excitation 360 nm, 
emission 465 nm) was measured with a SpectraFluor Plus (Tecan, Grödig, Austria) 
reader. Fluorescence of caspase-1-substrate (excitation 400 nm, emission 505 nm) 
was measured with a Varian Cary Eclipse fluorimeter (Varian, Darmstadt, Germany) 
Background was determined after incubating lysis buffer with substrate buffer and 
fluorescence of protein extracts was normalized to individual sample protein 
concentrations determined by BCA assay Kit (Perbio Science, Bonn, Germany). 
Caspase activity was inhibited by using the general caspase inhibitor Z-VAD-FMK 
(R&D Systems, Wiesbaden, Germany) or the caspase-1 inhibitor (Merck, Darmstadt, 
Germany). Z-VAD-FMK was applied 1 h or 6 h before glutamate damage at a final 
concentration of 50 µM. Caspase-1 inhibitor was applied 1 h before glutamate 
damage at a final concentration of 50 µM. 
2.4 RNA analysis 
For RNA extraction and subsequent analysis HT-22 neurons were grown at a density 
of 8 x 104 cells per well in 24-well plates. Primary rat neurons were cultured in PEI-
coated 60 mm culture dishes at 1 density of 1.5 x 106 cells per dish. 
2.4.1 RNA sample preparation 
For RT-PCR analysis, HT-22 neurons were harvested and then centrifuged at 179 x 
g, 4°C for 10 minutes and washed once in PBS. At least 4 wells per condition were 
pooled. Primary rat neurons (at least five 60-mm dishes per condition) were scraped 
in PBS, and centrifuged at 64 x g for 15 min at 4°C. The pellet was washed once in 
PBS. Then RNA-extraction was performed following the same procedure for HT-22 
and primary rat neurons. NucleoSpin RNA II Kit was used according to the 
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manufacturer’s protocol (Macherey und Nagel, Düren, Germany). Briefly, samples 
were dissolved in SDS-containing cell lysis buffer RA1 (Macherey und Nagel, Düren, 
Germany) and β-mercaptoethanol (Merck, Darmstadt, Germany). To separate 
insoluble cell fragments, samples were filtered through Nucleospin Filter units. 
Ethanol was added to the filtrate and the sample was loaded onto a Nucleospin RNA 
II column. Salt and DNA were removed by Membrane Desalting Buffer and a 
subsequent DNase reaction. Membrane was washed with Nucleospin buffer RA2 and 
RA3. Finally purified RNA was eluted from the column with RNase-free water. The 
RNA samples were stored at -80°C until further use. 
2.4.2 Determination of RNA amount 
To determine the RNA amount in the samples, 4 µl were diluted in 156 µl RNase-free 
water (Sigma-Aldrich, Taufkirchen, Germany). RNA amount was determined by UV, 
using micro cuvettes (Brand, Wertheim, Germany) in a Biophotometer (Eppendorf, 
Hamburg, Germany) at a wavelength of 260 nm. Reference wavelength was 280 nm. 
OD of 1 at 260 nM represents a concentration of 40 µg/ml RNA. 
2.4.3 Reverse transcriptase polymerase chain reaction (RT-PCR) 
2.4.3.1 Reverse transcription 
CDNA was derived from RNA samples by reverse transcription using a M-MLV-
reverse transcriptase and oligo-dT-primers; 5 µg total RNA were added to the 
following reaction components: 5 µl 10x PCR buffer (Abgene, Hamburg, Germany), 
2.5 µl dNTP mix [dATP, dCTP, dGTP, dTTP (Abgene, Hamburg, Germany) each 10 
mM], 2.5 µl D,L-dithiotreitol 0.4 mM, 2.5 µl Oligo-dT15-Primer (MWG-Biotech, 
Ebersberg, Germany) 100 µM, ad aqua dest. 45 µl. Sample was heated to 65 °C for 
5 minutes in a PX2 Thermal Cycler (Thermo electron corporation, Karlsruhe, 
Germany). Then 1 µl RNase inhibitor RNasin (40 U/µl, Promega, Mannheim, 
Germany) and 5 µl M-MLV reverse transcriptase (50 U/µl, Promega, Mannheim, 
Germany) were added and total sample was incubated for 1 h at 37°C. Finally, 
samples were heated at 95°C for 5 minutes. Derived cDNA was stored at -20°C until 
further use. 
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2.4.3.2 Polymerase chain reaction (PCR) 
The PCR was used to amplify the cDNA of AIF, Bid or glyceraldehyde-3-
phosphatedehydrogenase (GAPDH) to detectable amounts in the samples. The 
following primers were used: AIF, forward, 5’-GCG TAA TAC GAC TCA CTA TAG 
GGA GAT CCA GGC AAC TTG TTC CAGC-3’, and reverse, 5’-GCG TAA TACGAC 
TCA CTA TAG GGA GAC CTC TGC TCC AGC CCT ATC G-3’. Bid, forward, 5’-GCG 
TAA TAC GAC TCA CTA TAG GGA GAT GGG CTT CTG TCT AAG GAGA-3’, and 
reverse, 5’-GCG TAA TAC GAC TCA CTA TAG GGA GAA GTG AGG CCT TGT 
CTC TGAA-3’. For loading control, cDNA of housekeeping gene GAPDH was 
amplified, using the following primers: forward, 5’-CGT CTT CACCAC CAT GGA 
GAA GGC-3’ and reverse, 5’-AAG GCC ATG CCA GTG AGC TTC CC-3’. The 
resulting cDNA fragments had a length of 750 (AIF), 521 (Bid) and 400 (GAPDH) 
base pairs, respectively. The cDNA sample (10 µl) was added to the following 
reaction components: 4 µl 10x PCR reaction buffer IV (Abgene, Hamburg, Germany), 
1 µl dNTP mix [dATP. dCTP, dGTP, dTTP (Abgene, Hamburg, Germany) each 10 
mM], 3 µl MgCl2 25 mM (Abgene, Hamburg, Germany), 1 µl of forward and reverse 
primers (MWG-Biotech, Ebersberg, Germany) 10 µM, 5µl Thermoprime Plus 
polymerase 0.2 U/µl (Abgene, Hamburg, Germany), 25 µl aqua dest. PCR was 
performed in a PX2 Thermal Cycler (Thermo electron corporation, Karlsruhe, 
Germany) with an initial denaturation at 95°C for 2 min followed by 26-30 cycles of 30 
s 95°C, 1 min 57°C (AIF, GAPDH) or 60°C (Bid), and 2 min 72°C, and final extension 
at 70°C for 10 min. PCR products obtained for AIF, Bid or GAPDH gene were 
detected relative to control samples by ethidium bromide staining. 
2.4.4 Agarose gel electrophoresis 
Analysis of PCR amplification products was performed by fluorescence detection 
after agarose gel electrophoresis. To this end, 10 µl of each sample were mixed with 
bromophenol blue containing loading buffer 6x (2.4 ml EDTA solution 0.5 M, 12 ml 
glycerin, 5.6 ml aqua dest. and 0.04 g bromophenol blue) and were loaded onto a 
1.5% agarose gel containing ethidiumbromide. The gel was prepared by dissolving 
0.6 g agarose (Sigma-Aldrich, Taufkirchen, Germany) in 40 ml TBE buffer [10.8 g 
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trizma base, 5.5 g boric acid, 0.75 g disodium EDTA (all Sigma-Aldrich, Taufkirchen, 
Germany) ad 1000 m Millipore water], boiling everything up to 100°C and adding 40 
µl of a 0.5 mg/ml ethidiumbromide (Sigma-Aldrich, Taufkirchen, Germany) solution 
after cooling down to about 70 °C. The electrophoresis was performed for 70 minutes 
at 80 V. 10 µl of 50 bp DNA-ladder (Peqlab, Erlangen, Germany) were used as a size 
marker. PCR amplification products were detected under UV light (excitation 260 nm) 
by photographing the emission light (560 nm) of ethidium bromide in a UV chamber 
(Raytest, Straubehardt, Germany), equipped with a CCD Camera (Raytest, 
Straubehardt, Germany) controlled by Diana/NT 1.6 software. 
2.4.5 Statistical analysis 
All data are given as means ± standard deviation (SD). For statistical comparisons 
between two groups student’s t-test was used; multiple comparisons were performed 
by analysis of variance (ANOVA) followed by Scheffé's post hoc test. Calculations 
were performed with the Winstat standard statistical software package. 
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3 Results 
3.1 Glutamate-sensitivity of HT-22 neurons 
HT-22 neurons are immortalized hippocampal mouse neurons. They do not exhibit 
dendrites or axons and are an adhesive cell line with spindle shaped morphology. 
Glutamate (1-5 mM) induced cell death in HT-22 neurons (HT-22) in a concentration-
dependent manner (Figure 5). After exposure to glutamate, HT-22 neurons round up 
and detach from the well bottom. It is important to note that sensitivity to glutamate 
toxicity varies in HT-22 neurons depending on density and passage number of cells. 
For example, when seeded at a density of 60,000 cells per well HT-22 neurons 
exhibited less sensitivity against glutamate than at seeding densities of 40,000 cells 
per well, as shown in Figure 5. Therefore, experiments were always performed at 
different glutamate concentrations between 1-5 mM, and representative results are 
always shown from individual experiments where the respective glutamate 
concentration induced at least 50% cell death as detected with the MTT assay. The 
protective effects observed after treatment with siRNA or pharmacological inhibition 
were always robust over the whole range of glutamate concentrations. 
Figure 5: Glutamate toxicity 
Glutamate reduces viability of HT-22 neurons in a concentration-dependent manner as evaluated by 
the MTT assay 17 h after onset of the treatment. When seeded at a density of 40,000 cells per well, 
HT-22 were more sensitive against glutamate than at densities of 60,000 cells per well. 
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3.1.1 Bid translocates to mitochondria early during apoptosis 
Under physiological conditions, inactive Bid is distributed in the cytosol. The pro-
apoptotic activation of Bid is best characterized by Bid truncation and translocation of 
Bid to the mitochondria. To detect Bid translocation to the mitochondria after a 
glutamate challenge, HT-22 neurons were transfected with the pDsRed2-Bid vector 
which results in the expression of a red fluorescing Bid residing in the cytosol (Figure 
6). Mitochondria were stained with MitoTracker green immediately before treating the 
cells with glutamate. As shown in Figure 6 Bid translocated to mitochondria within 5 h 
after onset of the glutamate challenge, visualized by the co-localization of DsRed and 
MitoTracker Green fluorescence. 
Figure 6: Translocation of Bid after glutamate damage of HT-22 neurons 
Fluorescence photomicrographs of HT-22 neurons expressing a Bid-DsRed fusion protein show co-
localization of MitoTracker Green- and DsRed-signal in glutamate-damaged (5 mM, 5 h) cells. Similar 
results were obtained in cells exposed to 3 mM glutamate. Note, that the homogenous distribution of 
Bid observed in control cells significantly changes in glutamate-damaged cells where Bid accumulates 
at mitochondria (yellow in merged panels). 
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3.1.2 Bid knockdown attenuates oxidative stress and prevents cell death 
Bid-siRNA induced specific gene silencing of Bid as determined at mRNA and protein 
level. Messenger RNA and protein levels of housekeeping genes such as GAPDH 
and α-Tubulin were not affected by Bid-siRNA; the non-silencing mutant siRNA 
control sequence (mut-siRNA) did not alter Bid expression or any of the 
housekeeping genes (Figure 7A). Bid-siRNA significantly reduced glutamate-induced 
acceleration of reactive oxygen species (ROS) and attenuated glutamate-induced 
cell death as evaluated by DCF-fluorescence (Figure 7B) and MTT-assay (Figure 
7C), respectively.  
Figure 7: Bid-knockdown rescued HT-22 neurons from glutamate induced apoptosis. 
A. RT-PCR analysis of Bid mRNA (upper panels) and Western blot analysis of Bid protein (lower 
panels) in HT-22 neurons pretreated with 20 nM Bid-siRNA for 48h. RT-PCR with primers specific for 
GAPDH and anti-β-actin antibodies served for respective control analyses. B. Bid siRNA (20 nM, 48 h 
pretreatment) significantly reduces oxidative stress as evaluated by the DCF assay after exposure of 
HT-22 neurons to glutamate (2 mM) for 6 hours. ***p<0.001 compared to glutamate-exposed HT-22 
neurons pretreated with nonfunctional Mut-siRNA (Student’s t-test). C. Bid-siRNA significantly 
attenuated glutamate-induced cell death as determined by MTT assay. ***p<0.001 compared to 
glutamate-exposed HT-22 neurons pretreated with nonfunctional Mut-siRNA or vehicle Lipofectamine 
2000 (ANOVA, Scheffé’s). 
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3.1.3 Small molecule Bid inhibitor prevents glutamate-induced cell death 
In addition to the siRNA approach, the specific Bid inhibitor BI-6C9 was applied to 
confirm the essential role of Bid in glutamate-induced neuronal death. HT-22 neurons 
exposed to glutamate for 17 h show typical morphology of dying cells: the neuronal 
cells appear shrunken, rounded and detach from the culture dish (Figure 8A). HT-22 
neurons pretreated with the Bid inhibitor BI-6C9 retained their normal spindle-shaped 
morphology and were completely rescued from glutamate-induced cell death as 
determined by the MTT assay in experiments with different concentrations of 
glutamate (Figure 8A/B/C). Cells treated with the Bid inhibitor alone, showed an 
enhanced metabolic activity.  
Figure 8: Bid inhibitor BI-6C9 protects HT-22 neurons against glutamate-induced cell death. 
A. Photomicrographs (10x objective) show morphological evidence for severe damage of HT-22 
neurons 17 h after glutamate (4 mM) exposure. Glutamate-treated cells lose their spindle-like 
morphology, shrink and detach from the culture well bottom; in contrast, cells pretreated with the Bid 
inhibitor BI-6C9 (10µM) are fully protected against glutamate-induced death and are not different from 
the controls. B. Quantification of glutamate-induced (4 mM, 17 h) severe cell damage and the 
protective effect of BI-6C9 (10µM) by the MTT assay. C. Quantification of glutamate-induced (4 mM, 
17 h) weak cell damage and the protective effect of BI-6C9 (10 µM) by the MTT assay. Note; the 
protective effect of BI-6C9 is independent from the severity of the cell damage. ***p<0.001 compared 
to vehicle controls and BI-6C9-treated cells (ANOVA, Scheffé’s). 
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3.1.4 Prevention of glutamate-induced apoptosis by Bid inhibitor 
FACS analysis of FITC-Annexin-V-stained HT-22 neurons confirmed the pronounced 
protective effect of the Bid inhibitor against glutamate-induced apoptotic cell death 
(Figure 9A). Concomitant detection of propidium iodide (PI) revealed that less than 
9.4 ± 1.6% of the glutamate-treated cells were PI positive versus 5.4 ± 0.6% in the 
controls, suggesting that most HT-22 neurons exposed apoptotic features after 
glutamate exposure. Similar to the results obtained by Annexin binding analyses, the 
Bid inhibitor reduced the percentage of PI positive, i.e. necrotic cells to control levels 
(4.7 ± 0.3%) (Figure 9B).  
Figure 9: Bid inhibitor BI-6C9 protects HT-22 neurons against glutamate-induced apoptosis. 
A. FACS analysis of HT-22 neurons after FITC- Annexin-V labeling to detect apoptotic cells. Exposure 
to glutamate (3 mM, 17 h) resulted in enhanced Annexin-V binding of apoptotic HT-22 neurons 
compared to controls. BI-6C9 (10 µM, 1 h prior to damage) significantly reduced glutamate-induced 
apoptosis. ***p<0.001 compared to glutamate-treated cells (Student’s t-test). B. FACS analysis of 
necrotic HT-22 neurons after labeling with propidium iodide (PI). Note that the increase in PI positive 
cells (2-fold) after glutamate exposure is far less pronounced compared to the increase in Annexin-V-
labeling (6-fold). BI-6C9 (10 µM) treatment before glutamate-exposure significantly reduced the 
percentage of PI-positive cells to control levels. ***p<0.001 compared to glutamate-treated cells 
(Student’s t-test). 
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3.1.5 Specificity of the Bid inhibitor 
The specificity of BI-6C9 in the presently used culture system was confirmed in HT-
22 neurons transfected with a tBid expression vector. Overexpression of tBid 
reduced cell viability by approximately 40% (Figure 10) whereas cells pretreated with 
the Bid inhibitor were significantly protected from tBid-induced cell death (Figure 10). 
Figure 10: BI-6C9 prevents tBid-induced cell death. 
HT-22 neurons were pretreated with BI-6C9 (10µM, 1 h) before transfection with a tBid expressing 
plasmid (p-tBid). Twenty four hours later cell viability was determined with the MTT assay. ***p<0.001 
compared to controls and BI-6C9-treated cells (ANOVA, Scheffé’s). 
 
It is important to note that the percentage of cell death detected in tBid-transfected 
HT-22 neurons corresponds well to the transfection efficiency achieved with the 
current protocol for DNA vector transfection: Parallel transfection experiments in HT-
22 neurons with gene vectors encoding green fluorescent protein (GFP) of a 
comparable vector size of 4.7 kbp to 5.8 kbp and subsequent FACS analysis 
revealed a transfection efficiency of 44.7 ± 2.5% to 51.2 ± 1.2%, respectively (Figure 
11). 
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Figure 11: Efficiency of DNA vector transfections. 
HT-22 neurons were transfected with different GFP encoding gene vectors. Twenty four hours later 
the number of green fluorescing cells was determined by FACS analysis. 
 
3.1.6 Therapeutic time window of BI-6C9 
Strikingly, morphological analysis and MTT assay revealed that the Bid inhibitor BI-
6C9 rescued HT-22 neurons even when applied up to 6 h after glutamate-exposure, 
suggesting that Bid-mediated cell death depends on sustained Bid activation with a 
remarkable time window (Figure 12).  
Figure 12: BI-6C9 blocks HT-22 neuronal cell death applied up to 6h hours after glutamate. 
A. Photomicrographs of HT-22 MTT-incubated neurons after glutamate treatment (3 mM, 18 h) with or 
without BI-6C9 (10 µM, applied 2 h after onset of glutamate damage) B. Quantification of the MTT 
assay performed 18 h after onset of glutamate-treatment (3 mM) of HT-22 neurons. BI-6C9 was 
applied together with glutamate (0 h) or up to 6 hours afterwards. The graph shows mean values and 
S.D. of n=8 independent experiments per group; ***p<0.001 compared to glutamate treatment alone. 
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3.1.7 Bax inhibition does not protect against glutamate 
Bid and Bax are described as co-players in apoptotic processes of mitochondrial 
membrane permeabilization under various conditions [58, 60]. Therefore the effect of 
Bax inhibition in glutamate-induced apoptosis of HT-22 neurons was examined. In 
contrast to the findings with inhibition of Bid, blocking pro-apoptotic Bcl-2 family 
member Bax had no or only a very weak protective effect on HT-22 neurons as 
shown by MTT-assay, 18 hours after glutamate damage (Figure 13). Treatment of 
HT-22 neurons with Bax inhibitor alone increased the metabolic activity up to 140%. 
The protective effect of Bax inhibitor in glutamate-treated cells did not exceed the 
effect of the Bax inhibitor in control cells. 
Figure 13: No protection of HT-22 neurons by Bax inhibition. 
The Bax channel blocker (BaxI, 5 µM) was applied 1 h prior to exposure of HT-22 neurons to 
glutamate (1-2 mM, 17 h). The MTT assay revealed an enhanced metabolic activity by the BaxI in 
control cells. The BaxI only moderately preserved the metabolic activity in glutamate-treated cells, and 
this moderate protective effect did not exceed the effect of BaxI on metabolic activity in control cells. 
***p<0.001 compared to respective glutamate-treated cells. 
 
3.1.8 Mechanisms downstream of Bid 
Since Bid is supposed to act upstream mitochondrial damage, the involvement of Bid 
in the breakdown of mitochondrial membrane potential and subsequent activation of 
caspase-dependent and caspase-independent mechanisms was examined. 
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3.1.8.1 Effect of BI-6C9 on mitochondrial translocation of Bid 
To test the effect of BI-6C9 on the activation, i.e. the translocation of Bid to the 
mitochondria, confocal laser scanning microscopy of glutamate-treated HT-22 
neurons expressing DsRed-Bid and mitochondrial co-staining with MitoTracker was 
used. An inhibition of aggregation and mitochondrial translocation of Bid could be 
demonstrated in glutamate-treated groups with simultaneous addition of Bid inhibitor 
BI-6C9 to the damage medium. 
Figure 14: Bid inhibitor prevents translocation of Bid to the mitochondria. 
Fluorescence photomicrographs of HT-22 neurons expressing a Bid-DsRed fusion protein show co-
localization of MitoTracker Green- and DsRed-signal in glutamate-damaged (5 mM, 8 h) cells. Bid 
inhibitor BI-6C9 (10 µM) prevented the accumulation of Bid at the mitochondria and retained a 
homogenous distribution of Bid in the cytosol. 
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3.1.8.2  Mitochondrial membrane potential 
Staining with JC-1 was used to evaluate the effect of Bid inhibition on glutamate-
induced breakdown of the mitochondrial membrane potential. Glutamate treatment 
caused a significant loss of JC-1 red fluorescence, i.e. loss of mitochondrial 
membrane potential after glutamate treatment within 6-12 h (Figure 15A/B). In the 
HT-22 neurons, glutamate was as effective as carbonyl cyanide m-
chlorophenylhydrazone (CCCP) to induce mitochondrial membrane depolarization 
(Figure 15C). Pre-treatment with the Bid inhibitor prevented glutamate-induced 
breakdown of the mitochondrial membrane potential. 
Figure 15: Bid-inhibitor BI-6C9 prevents glutamate-induced mitochondrial depolarization. 
A. Mitochondrial membrane potential was analyzed by JC-1 fluorescence: upper panels show 
epifluorescence photomicrographs indicating equal cellular uptake of JC-1 by green fluorescence, 
lower panels depict intact mitochondria exposing red fluorescence. Glutamate-treated (3 mM, 12h) 
HT-22 neurons show significantly reduced red fluorescence compared to controls whereas BI-6C9 
(10µM) prevents the breakdown of the mitochondrial membrane potential as indicated by preservation 
of the red JC-1 fluorescence. B, C. FACS analyses of n=4 independent experiments per group reveal 
a decrease of the red JC-1 fluorescence to 20% of control levels 12h after glutamate-treatment (3 mM) 
which is prevented by BI-6C9. Glutamate treatment was as effective as the positive damage-control 
CCCP which causes a fast breakdown of the mitochondrial membrane potential. ***p<0.001 compared 
to controls and BI-6C9-treated cells (ANOVA, Scheffé’s). 
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In sum these data reveal, that Bid is activated after glutamate treatment of HT-22 
neurons, which leads to a breakdown of the mitochondrial membrane potential. Bid 
activation with subsequent mitochondrial membrane permeabilization may trigger 
both, caspase-dependent and caspase-independent execution of cell death through 
release of cytochrome c and AIF, respectively. Therefore, these caspase-dependent 
and caspase-independent mechanisms downstream mitochondrial damage were 
further examined. 
3.1.8.3 Bid inhibition reduces effector caspase-3 activity 
Measurements of caspase activity revealed a significant increase of caspase-3 
activity in HT-22 neurons after exposure to glutamate and this caspase activation 
was fully blocked by the Bid inhibitor (Figure 16).  
Figure 16: Bid inhibitor prevents glutamate induced activation of caspase-3. 
Caspase-3-activity assay revealed an increased caspase-3 activity after glutamate-treatment (2 mM, 
17h) that was prevented by BI-6C9 (10 µM). **p<0.01 compared to controls and BI-6C9-treated cells 
(ANOVA, Scheffé’s). 
 
3.1.9 Involvement of effector caspases in glutamate-induced apoptosis 
The data suggest activation of caspase-3 after glutamate-treatment of HT-22 
neurons, which could be blocked by BI-6C9. Therefore analyses regarding the 
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involvement of effector caspases in glutamate neurotoxicity were performed by using 
caspase-inhibitors and examination of lamin cleavage as an indicator of caspase-6-
activity. 
3.1.9.1 Inhibition of caspase-3 does not attenuate glutamate toxicity 
Significant inhibition of increased caspase-3 activity after the glutamate challenge 
was achieved with the membrane permeable general caspase inhibitor Z-VAD-FMK 
(Figure 17A). Although these and the data presented above implied an involvement 
of caspase-3 in the execution of glutamate-induced cell death in HT-22 neurons, the 
caspase inhibitor Z-VAD-FMK did not attenuate glutamate toxicity (Figure 17B). 
These data suggest that caspase-3 activation occurs after glutamate exposure in HT-
22 neurons but is not required for execution of the cell death program. 
Figure 17: Pan-caspase inhibitor fails to prevent glutamate-induced cell death in HT-22 
neurons.  
A. Increased caspase-3 activity in glutamate-treated HT-22 neurons was prevented by the pan-
caspase inhibitor Z-VAD-FMK (50 µM) applied 1 h before glutamate exposure proving the efficiency of 
Z-VAD-FMK under these experimental conditions. **p<0.01 compared to controls and Z-VAD-FMK-
treated cells, (ANOVA, Scheffé’s). B. The MTT-assay revealed that Z-VAD-FMK (50 µM) could not 
protect HT-22 neurons from glutamate-induced cell death. 
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3.1.9.2 Lamin cleavage in glutamate-induced neurotoxicity 
Cleavage of Lamin, a structure protein within the nuclear lamina, was examined as 
an indicator for the involvement of effector caspase-6 in glutamate-induced 
neurotoxicity. However, proteolytic activity indicating caspase-6 activity was not 
detected. Western blot analysis of total protein cell extracts with an antibody 
detecting Lamin A/C and respective caspase-6 cleavage products revealed that no 
cleavage of Lamin A occurred during glutamate-induced apoptosis of HT-22 neurons 
(Figure 18). 
Figure 18: Lamin cleavage was not detected during glutamate-induced neurotoxicity. 
Western blot analysis of total protein extracts. No cleaved lamin (28kDa) could be detected during 
glutamate damage (2 mM, 0-18 h) of HT-22 neurons. α-Tubulin band shows loading control. 
 
3.1.10 Involvement of AIF in apoptosis of HT-22 neurons 
Having shown that apoptosis induced by glutamate in HT-22 neurons does not 
require the activity of effector caspases, the involvement of AIF as a representative of 
mitochondrial caspase-independent pro-apoptotic factors was determined. Addition 
of 2 mM glutamate to immortalized hippocampal neurons induced translocation of 
AIF to the nucleus, as demonstrated by Western blot analysis and 
immunocytochemistry (Figure 19A/B) in fixed HT-22 neurons. 
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Figure 19: Nuclear translocation of AIF in glutamate-treated HT-22 neurons. 
A. Western blot analysis of AIF protein in the crude cytosolic and in the nuclear fractions before and 
after exposure to 2 mM glutamate. B. Confocal laser scanning microscope images of AIF 
immunoreactivity (green) under control conditions and after 18 h exposure to glutamate (2 mM) in 
immortalized hippocampal neurons (HT22 neurons). Counter staining with DAPI (dark blue) allowed 
the identification of nuclear translocation of AIF (AIF/DAPI, light blue). 
 
Confocal microscopy time laps recordings over a period of 18 h after glutamate 
exposure revealed that mitochondria containing AIF-GFP fusion protein translocated 
to the nucleus within 10 h after onset of the apoptotic challenge followed by a rapid 
release of AIF into the nucleus (see supplement movie). The movie was composed 
from fluorescence photomicrographs taken every 5 minutes from 7-14 h after onset 
of glutamate-treatment (3 mM) in HT-22 neurons expressing an AIF-GFP fusion 
protein. The movie shows accumulation of AIF around the nucleus in a damaged cell 
within 10 h after glutamate exposure. After accumulation around the nucleus AIF is 
released from mitochondria to the nucleus within 10-15 minutes followed by nuclear 
condensation and fragmentation of the cell. Co-localization of AIF-GFP- (green) and 
DAPI-signals (dark blue) reveal a nuclear localization of AIF (merged colour: light 
blue). 
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3.1.10.1 AIF-siRNA prevents glutamate-induced cell death 
Since the translocation studies implied a major role for AIF in glutamate-induced 
neuronal cell death, AIF gene silencing by siRNA was applied to further address this 
issue. AIF gene silencing on mRNA and protein level using a dsRNA dicer product 
(Figure 20A) significantly enhanced survival of HT-22 neurons exposed to glutamate 
(Figure 20B). 
Figure 20: AIF-knockdown by dicer product attenuates glutamate-induced neuronal cell death 
in HT-22 neurons. 
A. RT-PCR analysis of AIF mRNA (top rows) and Western blot analysis of AIF protein levels (bottom 
rows) in HT22 neurons pretreated with 20 nM AIF siRNA for 48 h. Controls were treated with mutant 
siRNA. RT-PCR with primers specific for GAPDH and anti-β-actin antibodies were used as controls for 
equal mRNA and protein amounts, respectively. HT22 neurons were pretreated with vehicle 
(Lipofectamine), nonfunctional mutant siRNA (mut-siRNA), or AIF-siRNA for 48 h. B. Cell viability was 
determined by the MTT assay, 20 nM mutant siRNA or AIF-siRNA for 48 h before 18 h 1-2 mM 
glutamate exposure. Cell viability in glutamate-exposed cultures pretreated with AIF-siRNA was 
significantly enhanced compared with controls (n=8; ***p<0.001; **p<0.01). 
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Of note, AIF-siRNA-treated HT-22 neurons surviving glutamate toxicity did not show 
nuclear AIF translocation (Figure 21), thereby stressing the specific role for AIF 
during the cell death process. 
Figure 21: No AIF-translocation in HT-22 neurons surviving glutamate treatment by AIF-siRNA. 
Confocal laser scanning microscope images of AIF immunoreactivity (green) and nuclear DAPI 
staining (dark blue). Downregulation of AIF by siRNA (dicer product, see above) resulted in inhibition 
of nuclear AIF translocation after 18 h of exposure to glutamate (2mM). 
 
Comparable results were also obtained with a single AIF-siRNA sequence (Figure 
22B), which also specifically reduced AIF mRNA and protein levels (Figure 22A). This 
confirmation experiment was performed to exclude possible unspecific off-target 
effects of the siRNA cocktail, which was obtained by the dicer reaction. On the one 
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hand, the single sequence was not as effective as the dicer product, because of the 
higher variety of the siRNAs obtained by the dicer reaction; on the other hand, the 
significant protective effect of the single sequence confirmed the conclusion that AIF 
plays an important role during glutamate-induced apoptosis of HT-22 neurons. 
Figure 22: AIF-siRNA attenuates glutamate toxicity in HT-22 neurons. 
A. AIF siRNA (20-40 nM) was applied to HT-22 neurons 48 h prior to analysis of mRNA levels by RT-
PCR (upper panels) or protein analysis by Western blot (lower panels). Non-functional Mut-siRNA or 
Lipofectamine 2000 (vehicle) was applied in control experiments, GAPDH or β-actin was analyzed as 
respective controls for RT-PCR or Western blot, respectively. B. AIF-siRNA (40-80 nM) was applied to 
HT-22 neurons 48 h prior to glutamate (2-3 mM). Cell viability was assessed by the MTT assay 18 h 
later. Mean values and S.D. of n=6 experiments per group are shown; *p<0.05, **p<0.01, and 
***p<0.001 compared to respective mut-siRNA treatments (ANOVA, Scheffé’s). 
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3.1.10.2 Bid inhibition prevents translocation of apoptosis inducing factor (AIF). 
To evaluate the role of Bid in mitochondrial AIF release and subsequent nuclear 
translocation, HT-22 neurons expressing AIF-GFP fusion protein were exposed to 
glutamate and AIF translocation to the nucleus in the presence or absence of the Bid 
inhibitor was analyzed (Figure 23). The Bid inhibitor BI-6C9 blocked glutamate-
induced AIF translocation as shown by confocal microscopy (Figure 23A) and 
Western blot analysis of cytosolic/mitochondrial and nuclear protein extracts (Figure 
23B). 
Figure 23: Bid-mediated glutamate toxicity requires AIF. 
A. Fluorescence photomicrographs of HT-22 neurons expressing a AIF-GFP fusion protein show co-
localization of GFP- and DAPI-signal in glutamate-damaged (2 mM, 17 h) cells. Bid inhibitor BI-6C9 
(10 µM) prevented the AIF translocation to the nucleus. B. Western blot analysis of cytosolic and 
nuclear protein extracts confirmed inhibition of glutamate-induced AIF translocation to the nucleus by 
the Bid inhibitor BI-6C9. 
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3.1.10.3 AIF-knockdown prevents tBid-induced cell death 
In addition, experiments with AIF-silenced HT-22 neurons showed, that siRNA-
mediated AIF knockdown prevented cell death induced by tBid-overexpression 
(Figure 24). This demonstrated that AIF mediates tBid-induced neurotoxicity.  
Figure 24: Bid-mediated cell death of HT-22 neurons requires AIF.  
HT-22 neurons were transfected with AIF-siRNA (50 nM) 24 h prior to transfection with a tBid-
expressing plasmid (1 µg). Analysis of cell viability by the MTT assay 24 h later revealed protection of 
HT-22 neurons against tBid-induced cell death by AIF-siRNA. ***p< 0.001 compared to p-tBid 
transfected cells (Student’s t test). Metabolic activity of HT-22 was neither affected by control plasmid 
3.1+ or the nonfunctional mut-siRNA. 
 
3.1.11 Mechanisms upstream of Bid-activation in glutamate neurotoxicity 
Several proteases have been demonstrated to act upstream of Bid cleavage and 
mitochondrial transactivation, including, for example, caspases, calpains and 
cathepsins [89, 90]. In addition poly(ADP-ribose) polymerase (PARP1) and 
poly(ADP-ribose) glycohydrolase (PARG) have been described as major key 
mediators of apoptotic signaling [86], especially for the translocation of AIF from 
mitochondria [91]. Also, mitogen-activated protein kinases (Map kinases) are 
discussed in the literature to play a role in apoptosis and the release of pro-apoptotic 
factors from mitochondria. For example, inhibition of p38 Map kinase prevented the 
release of mitochondrial pro-apoptotic factors, such as AIF in ceramide-induced 
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neuronal apoptosis [92]. Thus, the influence of specific inhibitors of these potential 
pro-apoptotic factors was examined in glutamate-challenged HT-22 neurons. 
3.1.11.1 Calpains 
Calpains do not play a role in apoptosis of HT-22 neurons caused by glutamate. Pre-
incubation of HT-22 neurons with the calpain inhibitor calpastatin in different 
concentrations, failed to prevent apoptosis induced by glutamate as determined by 
MTT-assay (Figure 25). 
Figure 25: Calpastatin does not protect HT-22 neurons from glutamate-induced apoptosis. 
Inhibitor of calpain (calpastatin 0.5-5 µM) was applied 1 h prior to exposure of HT-22 neurons to 
glutamate (3 mM, 17 h). MTT assay showed no protective effect of calpastatin against glutamate 
toxicity. 
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3.1.11.2 Cathepsins 
Cathepsins do not take part in mediation of apoptosis in HT-22 neurons after 
glutamate exposure. The Cathepsin inhibitor E-64-d showed no protective effect 
against glutamate toxicity in HT-22 neurons when applied one hour before glutamate-
exposure. This was shown by the MTT-assay (Figure 26). 
Figure 26: E-64-d showed no prevention of cell death in HT-22 neurons exposed to glutamate. 
Inhibitor of cathepsins (E-64-d 10-50 µM) was applied 1 h prior to exposure of HT-22 neurons to 
glutamate (3 mM, 17 h). MTT assay showed no protective effect of calpastatin against glutamate 
toxicity. 
 
3.1.11.3 P38 MAP kinase 
The p38 MAP kinase, a protein kinase involved in the cellular response to cytokines 
and stress does not participate in the mechanisms which are executed during 
glutamate treatment of HT-22 neurons. P38 MAP kinase phosphorylation was not 
altered during the cell death process (Figure 27A). Further, the involvement of p38 
was investigated by applying the p38 inhibitor SB 203580, which did not prevent 
apoptosis at any concentration in glutamate-treated HT-22 neurons (Figure 27B). 
M
et
ab
ol
ic
ac
tiv
ity
(%
 c
on
tr
ol
)
Vehicle
10µM E-64-d
50µM E-64-d
0
20
40
60
80
100
120
Control Glutamate
M
et
ab
ol
ic
ac
tiv
ity
(%
 c
on
tr
ol
)
3 Results  57 
Figure 27: No enhanced phosphorylation of p38 MAPK after glutamate treatment and no 
prevention of cell death by inhibition of p38 MAPK in HT-22 neurons. 
A. Western blot analysis of p38 MAP kinase phosphorylation in the total cell extract of HT-22 neurons 
before and after 6 hours of exposure to 3mM glutamate. Alteration of p38 phosphorylation was not 
detected. B. SB 203580 was applied 1h before glutamate-treatment of HT-22 neurons. Analysis of cell 
viability by the MTT assay 18 h later revealed no protection of HT-22 neurons against glutamate-
induced cell death by SB 203580. 
 
3.1.11.4 PARP1/PARG 
It is interesting to note that inhibition of PARP1, which plays a role in the release of 
AIF, protects HT-22 neurons from glutamate toxicity (Figure 28A). In contrast, PJ34 
did not protect HT-22 neurons against tBid-induced cell death. This result suggested 
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that PARP1 activation occurs upstream of Bid activation (Figure 28B). However, 
downregulation of PARG, which recently has been shown to be protective in cell 
death induced by oxidative stress, did not result in enhanced survival of HT-22 
neurons challenged with glutamate (Figure 28C). 
Figure 28: Inhibition of PARP1 but not PARG gene silencing reduces glutamate-induced cell 
death in HT-22 neurons. 
A. The PARP inhibitor PJ34 (10 µM) was applied 1 h before glutamate (2 mM) treatment. Cell viability, 
assessed by the MTT-assay 17 h later, showed attenuated decrease of metabolic activity in HT-22 
neurons pretreated with PJ34. B. HT-22 neurons were pretreated with PJ34 (10µM, 1 h) before 
transfection with a tBid expressing plasmid (p-tBid). Twenty four hours later cell viability was 
determined with the MTT assay. C. Cells were transfected with mutant siRNA or PARG-siRNA (40 nM, 
24 h) before glutamate exposure (3 mM, 18 h). Cell viability in glutamate-exposed cultures was 
significantly decreased by glutamate and was not influenced by PARG-siRNA. 
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3.1.11.5 Caspase-8 
Since Bid is well known as a target of caspase-8 [25], the involvement of caspase-8 
in glutamate-induced cell death was tested in HT-22 neurons. No activity of caspase-
8 in HT-22 neurons exposed to glutamate could be detected in the activity assay 
(Figure 29A), suggesting that this pathway of Bid activation was not activated. This 
was confirmed by showing in the MTT-assay, that blocking caspase-8 activity by the 
specific inhibitor Z-IETD-FMK did not rescue HT-22 neurons from glutamate toxicity 
(Figure 29B). 
Figure 29: Caspase-8 is not activated during glutamate-induced cell death of HT-22 neurons. 
A. Caspase-8 activity was analyzed in n = 4 independent experiments of the indicated treatment 
groups. Glutamate exposure (3 mM, 17 h) did not alter caspase-8 activity in HT-22 neurons. B. The 
specific caspase-8 inhibitor (Z-IETD-FMK, 50 µM) was applied 1 h prior to exposure of HT-22 neurons 
to glutamate (3 mM, 17 h). Evaluation of cell viability by the MTT assay showed that Z-IETD-FMK 
failed to exert protection against glutamate-induced HT-22 cell death. 
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3.1.11.6 Caspase-2 
DNA damage resulting from oxidative stress can lead to caspase-2 activation. Bid 
has been identified as a target of caspase-2 after cell death was induced by oxidative 
DNA damage. However, inhibition of caspase-2 by Z-VDVAD-FMK did not lead to an 
enhanced metabolic activity in glutamate-treated HT-22 neurons, as determined by 
the MTT-assay 17 hours after glutamate exposure (Figure 30). 
Figure 30: Inhibition of caspase-2 does not protect HT-22 neurons from glutamate. 
The specific caspase-2 inhibitor (Z-VDVAD-FMK, 5-50 µM) was applied 1 h prior to exposure of HT-22 
neurons to glutamate (3 mM, 17 h). Evaluation of cell viability by the MTT assay showed that Z-
VDVAD-FMK failed to protect against glutamate-induced HT-22 cell death. 
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3.1.11.7 Caspase-1 
It has been reported, that caspase-1 is involved in hypoxia-induced Bid cleavage and 
in the burst of ROS levels after glutamate toxicity in neurons [21, 80]. In line with 
these previous findings, the caspase-1 inhibitor (ICE inhibitor II) attenuated glutamate 
toxicity in HT-22 neurons (Figure 31), but this protective effect was rather moderate 
compared to the pronounced protection achieved with the Bid inhibitor, in particular 
at high glutamate concentrations. 
Figure 31: Moderate protection by caspase-1-inhibition. 
Inhibitor for caspase-1 (ICE-inhibitor II, 1-25 µM was applied 1 h prior to exposure of HT-22 neurons to 
glutamate (2-3 mM, 17 h). Evaluation of cell viability by the MTT assay showed a moderate protective 
effect of the caspase-1 inhibitor. . **p<0.01 and ***p<0.001 compared to glutamate-treated cells 
(ANOVA, Scheffé’s). 
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3.1.11.8 Omi/HtrA2 
In addition to the established potential proteases involved in Bid cleavage and AIF 
release, next the involvement of the serine protease Omi/HtrA2, which supports 
caspases by cleaving IAPs or caspase-independent pathways through its protease 
activity, was addressed [93, 94]. The MTT assay revealed a pronounced 
concentration-dependent protection by the Omi/HtrA2 inhibitor UCF-101 [38] (Figure 
32A/B). 
Figure 32: Involvement of Omi/HtrA2 activity in glutamate neurotoxicity. 
A, B. The Omi/HtrA2 inhibitor UCF-101 (10-20µM) attenuates glutamate-induced cell death. UCF-101 
was applied 1 h prior to glutamate exposure and cell viability was assessed by the MTT assay 18 h 
later. ***p<0.001 compared to glutamate-treated cells (ANOVA, Scheffé’s). 
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Moreover, the Omi/HtrA2 inhibitor prevented mitochondrial release and translocation 
of AIF to the nucleus of HT-22 neurons exposed to glutamate as shown in confocal 
microscopy pictures of HT-22, expressing the AIF-GFP fusion protein (Figure 32). 
Figure 32: Inhibition of Omi/HtrA2 prevents AIF translocation in glutamate-treated HT-22 
neurons. 
Omi/HtrA2 inhibitor UCF-101 (10 µM) prevents AIF translocation in AIF-GFP fusion protein-transfected 
HT-22 neurons exposed to glutamate. HT-22 neurons expressing AIF-GFP fusion protein (green) were 
treated with glutamate for 18 h, before staining with DAPI (blue) and analysis by confocal fluorescent 
microscopy. Glutamate-treated cells show translocation of AIF to the nucleus, whereas in controls and 
UCF-101-treated cells AIF remains located in the mitochondria. 
D
A
PI
A
IF
-G
FP
M
er
ge
Control UCF-101 Glutamate
UCF-101 +
Glutamate
20µm
D
A
PI
A
IF
-G
FP
M
er
ge
3 Results  64 
However, UCF-101 did not prevent tBid neurotoxicity (Figure 33), suggesting that 
Omi/HtrA2 does rather act upstream than downstream of Bid-mediated mitochondrial 
demise.  
Figure 33: No protective effect of UCF-101 against tBid neurotoxicity. 
HT-22 neurons transfected with tBid expression vector showed reduced viability as assessed by MTT 
assay 24 h later. The Omi/HtrA2 inhibitor UCF-101 (10µM) failed to attenuate tBid-induced cell death 
in HT-22 neurons. Controls were transfected with an empty vector (pcDNA 3.1+). 
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This could be confirmed by the finding that HT-22 neurons pre-treated with AIF-
siRNA, showed no enhanced protection against glutamate toxicity by additional 
application of the Omi/HtrA2 inhibitor UCF-101 (Figure 34). AIF-siRNA and UCF-101 
alone exhibited similar significant protective effects in HT-22 neurons exposed to 
glutamate. When applied together, AIF-siRNA and UCF-101 showed no better 
protection of HT-22 neurons than AIF-siRNA in the UCF-101 lacking groups or UCF-
101 in mut-siRNA- or un-transfected groups.  
Figure 34: UCF-101 and AIF-siRNA protect HT-22 neurons against glutamate toxicity, but not in 
an additional manner.  
AIF-siRNA (15 nM) was applied to HT-22 neurons 48 h prior to glutamate (1 mM) treatment which was 
performed on presence or absence of UCF-101 (10 µM). Cell viability was assessed by the MTT 
assay 18 h later. ***p<0.001 compared to glutamate-treated cells. Together, AIF-siRNA and UCF-101 
showed no additional protective effect. 
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Similar to the caspase-1 inhibitor, the Omi/HtrA2-inhibitor provided only moderate 
protection when HT-22 neurons were exposed to high concentrations of glutamate 
(Figure 35). Compared with BI-6C9, UCF-101 never achieved protection efficiency as 
pronounced as the Bid inhibitor. A combination of caspase-1 inhibitor and UCF-101, 
however, provided an additive effect resulting in near complete protection against 
glutamate toxicity at moderate cell damage (60% with 3 mM glutamate) but not after 
severe cell damage (80% with 4 mM glutamate) (Figure 35).  
Figure 35: Inhibition of Omi/HtrA2 and caspase-1 exert additive protection against glutamate 
toxicity. 
The caspase-1 inhibitor (ICE-Inhibitor, 25 µM) and UCF-101 (10 µM) were applied separately or in 
combination 1 h before exposure of HT-22 neurons to glutamate. Cell viability was determined 18 h 
later by the MTT assay. Note, that the caspase-1 Inhibitor and UCF-101 exert additive effects. The 
graph shows mean values and SD of 8 experiments per group. **p<0.01, ***p<0.001 compared to the 
respective glutamate-treated cells. ♣♣p<0.01, ♣♣♣p<0.001 compared to caspase-1 inhibitor 
pretreated cells. ♦♦p<0.01, ♦♦♦p<0.001 compared to the UCF-101 pretreated cells. 
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It is interesting to note that a combination of UCF-101 and the general caspase 
inhibitor (Z-VAD-FMK) exerted no additive protective effect against glutamate toxicity 
(Figure 36) as combinations of UCF-101 and the caspase-1 inhibitor (ICE inhibitor II) 
did. This suggests that the general caspase inhibitor did not efficiently block caspase-
1, likely due to different IC50 values of Z-VAD-FMK for the different caspases. 
Figure 36: Combination of UCF-101 and Z-VAD-FMK did not exert additive protection against 
glutamate toxicity.  
The general caspase inhibitor (Z-VAD-FMK, 50 µM) and UCF-101 (10 µM) were applied separately or 
in combination 1 h before exposure of HT-22 neurons to glutamate. Cell viability was determined 18 h 
later by the MTT assay. Note, that there was no additive effect when UCF-101 and Z-VAD-FMK were 
applied in combination. The graph shows mean values and SD of 8 experiments per group. ***p<0.001 
compared to glutamate-treated cells. 
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Since the data above suggested a role for Omi/HtrA2 upstream the activation of Bid, 
the ability of Omi/HtrA2 to cleave Bid was checked. However, recombinant serine 
protease Omi/HtrA2 was neither able to cleave Bid nor to accelerate Bid cleavage 
mediated by caspases in HT-22 cell protein extracts containing full length Bid (Figure 
37A/B) suggesting that caspases can activate Bid in a direct manner while Omi/HtrA2 
may operate through different mechanisms and acts on Bid in an indirect manner. 
Figure 37: Bid is not a direct target of Omi/HtrA2. 
A. Total protein extracts of HT-22 neurons were exposed to recombinant Omi/HtrA2 or caspase-8 for 
10 min. Immunoblot analysis of the incubated extracts with a Bid antibody reveals Bid cleavage by 
caspase-8 but not by Omi/HtrA2. B. Total protein extracts of HT-22 neurons were exposed to 
recombinant caspase-1 [100 U], Omi/HtrA2 or a combination of both proteins for 10 min. Immunoblot 
analysis show Bid cleavage by 100 U of caspase-1. Bid cleavage was not detected at caspase-1 
incubation in presence of its specific inhibitor (ICE inhibitor II, 25 µM), and neither Omi/HtrA2 alone nor 
combinations of both proteases resulted in enhanced Bid cleavage. 
 
3.2 Bid and AIF are not required in staurosporine-
induced apoptosis 
It remained to be clarified, however, whether this Bid-dependent pathway was a 
specific feature of glutamate-induced cell death or a general mechanism of apoptosis 
in neurons. Therefore, effects of the Bid inhibitor and AIF-siRNA were investigated 
after induction of apoptosis by staurosporine, an inducer of caspase-dependent 
apoptosis. 
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3.2.1 No protection from STS-induced cell death by Bid-inhibition 
The Bid inhibitor BI-6C9 did not prevent STS-induced cell death as confirmed by the 
MTT assay (Figure 38A) and did not reduce the percentage of Annexin-V-positive 
cells after STS-damage in HT-22 neurons as confirmed by Annexin-V / PI-staining 
(Figure 38B/C). 
Figure 38: Bid is not required for staurosporine-induced apoptosis in HT-22 neurons. 
A. Cell viability of HT-22 was determined by MTT assay 18 h after treatment with STS (300 nM). 
Pretreatment of HT-22 neurons with 10 µM BI-6C9 1 h prior to onset of STS treatment did not 
attenuate cell death. B. FACS analysis of HT-22 neurons binding FITC-labeled Annexin-V 18 h after 
exposure to staurosporine (300 nM). The Bid inhibitor BI-6C9 (10 µM, 1 h prior to damage) did not 
reduce apoptosis induced by STS. C. FACS analysis of necrotic HT-22 neurons after labeling with 
propidium iodide (PI). Note that the increase in PI positive cells after STS exposure (300 nM) is far 
less pronounced compared to the increase in Annexin-V-labeling. BI-6C9 (10 µM) treatment before 
STS-exposure did not significantly affect the percentage of PI positive cells to control levels. 
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3.2.2 STS-induced cell death does not involve AIF translocation 
Analysis of AIF translocation after the STS challenge in AIF-GFP fusion protein 
transfected HT-22 neurons revealed that AIF was not released from mitochondria 
and did not translocate to the nucleus in damaged neurons (Figure 39).  
Figure 39: AIF does not translocate to the nucleus in STS-treated neurons. 
HT-22 neurons expressing AIF-GFP fusion protein (green) were treated with STS for 18 h, before 
staining with DAPI (blue) and analysis by confocal fluorescent microscopy. The Bid inhibitor BI-6C9 
does not prevent DNA condensation and nuclear fragmentation of HT-22 neurons, and AIF remains 
located in the mitochondria of and does not translocate to the nucleus of damaged cells. 
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3.2.3 AIF-knockdown does not rescue HT-22 neurons from apoptosis by STS-
treatment 
After demonstrating a non-involvement of AIF in STS-induced apoptosis, AIF gene 
silencing by AIF-siRNA transfection did not affect STS-induced apoptosis, neither. In 
contrast, there was a pronounced protection against glutamate toxicity. 
Figure 40: AIF is not required for staurosporine-induced apoptosis in HT-22 neurons. 
Cells were transfected with mutant siRNA or AIF-siRNA (20 nM, 48 h) before STS (300 nM, 18 h) 
exposure. Cell viability in STS-exposed cultures was significantly decreased by STS and was not 
influenced by AIF-siRNA. 
 
3.3 Role of Bid and AIF in glutamate-induced apoptosis 
of primary rat neurons 
Since HT-22 neurons do not express glutamate receptors, they can not be used as a 
model for excitotoxic glutamate damage as it occurs in primary rat neurons for 
example in stroke and brain trauma. But glutamate-induced apoptosis in HT-22 
neurons as well as excitotoxicity induced by glutamate in primary neurons, both end 
up in an increase of reactive oxygen species and subsequent mitochondrial damage. 
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Therefore, glutamate damage of HT-22 neurons was used as a reproducible, easy to 
handle model of apoptosis in neuronal cells. To confirm the data found in HT-22 
neurons, different tests in primary rat neurons were established. Thereby a key role 
for AIF and Bid was found as it was pronounced in glutamate-induced apoptosis of 
HT-22 neurons. 
3.3.1 AIF-knockdown rescues primary neurons from apoptosis 
In primary hippocampal neurons, AIF-siRNA (dicer product) induced complete loss of 
AIF mRNA within 48 h and significant reduction of AIF protein 48 h after onset siRNA 
treatment (Figure 41A). Housekeeping proteins such as GAPDH or α-Tubulin were 
not affected by AIF-siRNA, and mutant siRNA control sequences affected neither AIF 
mRNA nor protein levels nor the housekeeping proteins GAPDH or α-Tubulin (Figure 
41A). SiRNA-mediated knock-down of AIF resulted in a significant reduction of 
apoptotic nuclei after glutamate-induced neuronal cell death (Figure 41B). After 
glutamate treatment, >90% of cells displayed condensed nuclei in control cultures, 
whereas only 58 ± 8% of AIF-siRNA-treated cells showed signs of nuclear apoptosis 
(p <0.01) (Figure 41C). 
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Figure 41: Reduced glutamate-induced apoptosis in primary neurons pretreated with AIF-
siRNA. 
A. AIF mRNA and protein were significantly downregulated, as demonstrated by RT-PCR (top 2 rows) 
and Western blot analysis (bottom 2 rows), respectively, in primary hippocampal neurons pretreated 
with AIF-siRNA for 48 h. RT-PCR for GAPDH (bottom) and Western blotting for α-tubulin were 
performed as controls. B. Fluorescence microscope images of DAPI-stained embryonic hippocampal 
neurons were obtained after 48 h of exposure to 20 µM glutamate in EBSS medium. Only cultures 
pretreated with 20 nM AIF-siRNA contained >50% healthy nuclei, whereas all other glutamate-treated 
groups showed >85% pyknotic and/or fragmented nuclei, indicating apoptotic damage (Glutamate, 
right column). The respective control cultures with EBSS medium contained only very few apoptotic 
nuclei (Control, left column). C. Primary hippocampal neurons were left untreated (Controls) or were 
pretreated with 20 nM nonfunctional mutant siRNA (mut-siRNA), or 20 nM AIF-siRNA for 48 h. On day 
9, cells were exposed to 20 µM glutamate in EBSS medium for 48 h. Thereafter, neurons were fixed 
with paraformaldehyde, and apoptotic nuclei were quantified after staining with DAPI. Pretreatment 
with AIF-siRNA significantly reduced apoptotic cell death compared with the other cultures exposed to 
glutamate (n=4; **p<0.01 versus all other glutamate-treated groups). 
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3.3.2 Bid inhibitor prevents translocation of AIF 
Inhibition of Bid by 2 µM BI-11A7, which was always applied in primary neurons, 
because of the insolubility of BI-6C9 in EBSS, reduced nuclear AIF translocation and 
neuronal cell death after glutamate treatment (20 µM, 6 h) compared to control levels 
(Figure 42A/B). This result suggests that similar to glutamate-induced apoptosis in 
HT-22 neurons, in excitotoxic apoptosis of primary cortical neurons nuclear AIF 
translocation occurs downstream of Bid activation and that Bid may be responsible 
for the release of AIF from mitochondria. 
Figure 42: BI-11A7 prevents AIF translocation after excitotoxicity by glutamate in primary 
cortical neurons. 
A. Immunostaining of rat embryonic cortical neurons shows translocation of AIF (green fluorescence) 
to the nucleus 6 h after exposure to glutamate. Pretreatment with BI-11A7 (2 µM) preserves nuclear 
morphology (blue fluorescence, Hoechst 33342) and prevents AIF translocation. B. Quantification of 
AIF positive nuclei in rat embryonic neurons exposed to glutamate (20 µM) for 6 h. Mean values and 
SD of four dishes per group are presented. ***p<0.001 compared to glutamate-treated cells. 
 
3.3.3 Bid-inhibition prevents apoptosis of primary rat neurons 
In addition it could be shown that prevention of AIF translocation in primary neurons 
resulted in the prevention of cell death, i.e. apoptosis. Pretreatment with Bid inhibitor 
BI-11A7 1 h prior to glutamate (20 µM, 24 h) exposure showed a significant reduction 
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of apoptotic nuclei (Figure 43A). After glutamate treatment, >80% of cells displayed 
condensed nuclei in control cultures, whereas only 25% of BI-11A7-pretreated cells 
showed signs of nuclear apoptosis (Figure 43B). It is interesting to note that the Bid 
inhibitor provided neuroprotective effects in a dose dependent manner. Quantification 
of pyknotic nuclei could be confirmed by the MTT-assay.  
Figure 43: Bid inhibitor BI-11A7 prevents excitotoxicity-induced apoptosis of primary rat 
hippocampal and cortical neurons. 
Hippocampal (A) or cortical (B, C) neurons were pretreated with BI-11A7 at the indicated 
concentrations 1 h before exposure to glutamate (20 µM) in EBSS. After 24 h, apoptotic nuclei were 
quantified after staining with Hoechst 33342. C. In a separate experiment, the protective effect of BI-
11A7 against glutamate-induced cell death was quantified by the MTT-assay. The graphs show mean 
percentages of apoptotic nuclei (A) or cell viability (C) and SD of five separate dishes per group. 
***p<0.001 compared with glutamate-treated cells (ANOVA, Scheffé’s). 
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4 Discussion 
The present thesis demonstrates a key role for Bid in mitochondrial membrane 
permeabilization and the subsequent release of AIF after glutamate-induced cell 
death in HT-22 neurons. Both, Bid gene silencing and pharmacological inhibition of 
Bid significantly protected HT-22 neurons against glutamate toxicity and inhibition of 
Bid prevented breakdown of mitochondrial membrane potential and AIF translocation 
to the nucleus. Strikingly, AIF gene silencing prevented tBid induced neurotoxicity, 
which strongly suggests a particular role for AIF and thus caspase-independent 
execution of cell death downstream of Bid. Many factors which have been previously 
discussed to mediate the activation of Bid, including calpains, cathepsins and 
caspase-2 were not found to be involved in glutamate-induced apoptosis of HT-22 
neurons. In contrast, caspase-1 and Omi/HtrA2 were suggested to act upstream 
mitochondrial damage and to be involved in the activation of Bid. Additionally, it has 
been demonstrated that excitotoxic cell death in primary neurons depends on Bid 
and AIF as well. Therefore, it is proposed that the model of glutamate-damage in HT-
22 is relevant for mechanisms involved in excitotoxic cell death of primary neurons.  
4.1 Glutamate damage in HT-22 neurons: A model for 
oxidative stress induced apoptosis 
Glutamate causes cell death in HT22 neurons by oxidative stress, not by 
excitotoxicity through glutamate receptor-mediated calcium influx. In HT-22 neurons, 
which lack functional glutamate receptors, glutamate blocks the glutamate-cystine 
antiporter system [20]. Therefore, cysteine, which is required for glutathione 
synthesis, is missing and glutathione levels decrease in the cell. As a consequence, 
levels of reactive oxygen species (ROS) increase within a few hours after glutamate 
treatment of HT-22 neurons by the initial breakdown of the free radical detoxification 
system. This initial ROS formation leads to mitochondrial damage which is the reason 
for a secondary explosive burst of ROS levels [21]. In addition, an elevation of 
cytosolic calcium levels occurs [95], similar to the increase of calcium levels induced 
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by excitotoxicity in primary neurons, which suggests glutamate toxicity in HT-22 
neurons as an adequate model for glutamate-induced cell death of neurons. Bid-
siRNA significantly inhibited the burst of free radical generation in HT-22 neurons 
exposed to glutamate suggesting that the initial oxidative stress by glutathione 
depletion requires Bid-mediated mitochondrial amplification. Therefore, the present 
findings expose Bid as a major mediator of ROS-induced cell death through 
mitochondrial pathways. It is important to note that the small molecule Bid inhibitors 
do not prevent cell death after exposure to H2O2. This excludes free radical 
scavenger properties of these Bid inhibitors. In contrast to the protective effect by 
inhibition of Bid, inhibition of Bax, a Bcl-2 family member which interacts with Bid to 
permeabilize the mitochondrial membrane [96], could not protect HT-22 neurons from 
glutamate damage. Similar results were obtained in excitotoxicity-induced apoptosis 
in primary neurons. In these primary cells, Bax-knockdown had not protective effect, 
whereas knockdown of Bid and AIF protected neurons against glutamate [Cardoso et 
al., FENS meeting, Vienna, 2006]. These findings and the current results of this 
thesis indicate a major involvement of Bid in mitochondrial damage and the 
subsequent execution of apoptosis, which may occur independently of the interaction 
of Bid with Bax. 
4.2 Bid-dependent AIF-release in glutamate-induced 
apoptosis of HT-22 neurons 
A second important aspect of the present study addresses the role of AIF mediating 
caspase-independent cell death downstream of Bid activation. Using the AIF-GFP 
construct mitochondrial release of AIF and translocation to the nucleus could be 
demonstrated, which occurred around 8-10 h after the onset of glutamate exposure. 
Time laps video recordings showed that the time point of massive AIF translocation 
to the nucleus after onset of the glutamate challenge may vary from cell to cell, but 
once started, the AIF translocation takes place within 15 min and is followed by rapid 
nuclear condensation and fragmentation of the cells. AIF-siRNA significantly 
attenuated glutamate-induced neurotoxicity in HT-22 neurons (Figure 20, 22) and in 
primary neurons (Figure 41); most intriguingly, AIF siRNA prevented tBid-induced cell 
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death in HT-22 neurons, clearly demonstrating that Bid-induced cell death was 
executed by AIF. Of note, confocal microscopy of AIF-GFP expressing HT-22 
neurons as well as western blot analysis of cytosolic and nuclear protein extracts 
revealed that the Bid inhibitors prevented the translocation of AIF from mitochondria 
to the cytosol. These results suggest that AIF dominates the potential pathways to 
neuronal cell death triggered by Bid after the glutamate challenge. This finding is well 
in line with recent data where we and others demonstrated a key role for AIF in 
delayed neuronal cell death after excitotoxic, or hypoxia/ischemia insults in vitro and 
in vivo. It has been shown that Hq mice, which express only about 20% AIF in 
comparison to their wildtype littermates, exhibit protection against different stimuli 
such as excitotoxicity by glutamate or kainate or even ischemia by middle cerebral 
artery occlusion (MCAO). Similar results were obtained in the corresponding in vitro 
models of glutamate and kainate toxicity or oxygen-glucose deprivation [97, 98].  
Further, these results propose that the release of pro-apoptotic factors is a 
coordinated process where the release of a particular apoptotic factor and its role in 
the execution of apoptosis also depends on the stress challenge and the pathway to 
mitochondrial damage. Very little is known on the proposed regulated release of 
particular mitochondrial factors in apoptotic cells and in damaged neurons in 
particular. Recent data demonstrated that AIF release requires cleavage of the 
protein which is localized at the inner membrane of the mitochondrial intermembrane 
space [99, 100], and possible candidates for such proteolytic processing of AIF for 
mitochondrial release are, for example, calpains [75]. However, other proteases 
which may be activated independent of calcium levels have been postulated but not 
yet identified to mediate such AIF processing [100]. In addition, inhibition of poly 
(ADP-ribose) polymerase 1 (PARP1), a molecule responsible for neuronal cell death 
for example after cerebral ischemia [101], resulted in an attenuated damage of HT-22 
neurons after glutamate exposure. These results confirmed previous studies which 
demonstrated a protective effect of PARP1 inhibition in oxygen glucose deprivation of 
primary neurons and focal cerebral ischemia in mice [98]. In these models it has 
been suggested that mitochondrial NAD+ depletion, which is caused by 
overactivation of PARP1, may represent the link between PARP activation and the 
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release of AIF from mitochondria [91]. In contrast, inhibition of PARP1 was not able 
to prevent cell death in HT-22 neurons overexpressing tBid. Together these data 
suggest that activation of PARP1 during glutamate-damage of HT-22 neurons leads 
to a decrease of mitochondrial NAD+ that induces Bid-mediated translocation of AIF 
to the nucleus, in which it initiates nuclear condensation [102]. Silencing of the poly 
(ADP-ribose) glycohydrolase gene (PARG) has been recently shown to be protective 
in H2O2-treated MCF-7 and HeLa cells [86]. In these models, the catabolism of poly 
(ADP) ribose (PAR) was delayed, and cells were protected against genotoxic stress, 
suggesting that not PAR accumulation, but fast PAR degradation is a trigger of 
genotoxic stress-induced apoptosis. In our model, HT-22 neurons were not protected 
against glutamate by PARG knockdown with PARG-siRNA, suggesting that PAR 
degradation does not play a leading part in glutamate toxicity in this model system.  
Other mitochondrial pro-apoptotic factors than AIF may as well be located in 
particular compartments of the mitochondrial intermembrane space and may require 
activation of different release mechanisms [103, 104]. For example, recent studies 
provided evidence for the entrapment of cytochrome c in the mitochondrial cristae, 
and the release of cytochrome c during apoptosis required disruption of Optic 
Atrophy 1 (OPA1) oligomers [105, 106]. The proposed differential distribution and 
individual mechanisms of release from the mitochondrial intermembrane space may 
explain why AIF release occurs as an early event and is independent of the release 
of other pro-apoptotic factors after ischemic or excitotoxic brain lesions. In line with 
this model, our data propose a preferential release of AIF from mitochondria in 
glutamate-induced cell death in neurons that is not compensated after AIF gene 
silencing by cytochrome c release and caspase-dependent mechanisms. 
4.2.1 Caspase-dependent versus caspase-independent apoptosis 
It has been well established that mitochondrial membrane permeabilization results in 
the release of pro-apoptotic factors such as cytochrome c, Smac/Diablo, Omi/HtrA2 
and AIF, which may execute cell death via caspase-dependent or caspase-
independent mechanisms. For example, formation of the apoptosome by cytochrome 
c, Apaf-1 and procaspase-9 and downstream catalytic activation of executor 
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caspases (caspase-3, -6, or -7) is a widely established mechanism of caspase-
dependent cell death execution downstream of mitochondrial damage in many cells, 
including neurons. In the present study, activation of caspase-3 downstream of Bid 
was detected suggesting that this pathway was also activated in HT-22 neurons. 
Caspase-3 inhibition alone, however, did not prevent glutamate-induced cell death 
(Figure 17) and other indicators of executor caspase activities, as for example lamin 
cleavage as a prerequisite for caspase-6, were also not detected (Figure 18). 
Similarly activation of caspase-8, which is widely described as an initiator in caspase-
dependent apoptosis upstream of Bid, was not detected (Figure 29), and the specific 
caspase-8 inhibitor did not protect the neurons against glutamate toxicity. Previous 
findings in cerebral ischemia of mice demonstrated that AIF release and caspase-3 
activation occurred in parallel [98] as found here in the glutamate-damage model of 
HT-22 neurons. However, the present and the previous studies suggested a merely 
partial involvement of caspase-3 in these models of neuronal apoptosis. Strikingly, 
inhibition of caspase-3 had no protective effect in glutamate-treated HT-22 neurons 
which is in line with findings in cerebral ischemia of mice where only a part of the 
detected apoptotic DNA fragmentation was associated with caspase-3 activity [98]. In 
contrast, previous findings demonstrated that caspase-3 knock-out mice showed 
neuroprotection in models of cerebral ischemia [70]. However, this protective effect 
was less pronounced than anticipated regarding the strong evidence for caspase 
activation in ischemic brain tissue. In the present in vitro models, AIF gene silencing 
did not push cells toward caspase-3-mediated cell death. In sum these data strongly 
suggest a major role for AIF-mediated caspase-independent execution of apoptotic 
cell death downstream of mitochondrial membrane permeabilization. This fits well 
with observations in vivo, where AIF translocation to the nucleus of ischemic neurons 
occurred prior to detectable caspase activation and correlated well with signs of cell 
death; further, in models of cerebral ischemia protective effects in animals with low 
AIF protein levels were far more pronounced than protective effects in caspase-
knockout animals or after caspase inhibition [65, 98, 107]. 
Another mitochondrial factor that has been linked to caspase-dependent as well as 
caspase-independent apoptosis is the serine protease Omi/HtrA2 [93, 94]. Omi/HtrA2 
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is localized in the mitochondria and in the cytosol and after apoptotic stress 
increased mitochondrial release of activated Omi/HtrA2 may lead to proteolysis of 
IAPs, in particular cleavage of XIAP or survivin, and subsequent acceleration of 
caspase activity [93, 94, 108-110]. In addition Omi/HtrA2 can mediate cell death 
through caspase-independent mechanisms through its serine protease activity [39, 
94]. In contrast, in Omi/HtrA2 knock-out mice, it has been shown that Omi/HtrA2 
plays a neuroprotective role for striatal neurons. Mice lacking the Omi/HtrA2-gene, 
developed a parkinsonian phenotype, that led to death around 30 days after birth 
[111]. However, a recent study demonstrated protective effects of the Omi/HtrA2 
inhibitor UCF-101 in a model of focal cerebral ischemia, suggesting a pro-apoptotic 
role for Omi/HtrA2 in acute ischemic neuronal death [37]. Furthermore, Omi/HtrA2 
plays a role in apoptotic cell death after myocardial ischemia [112]. These data 
suggest that, similar to AIF, Omi/HtrA2 plays an important role in the maintenance of 
neurons under physiological conditions but takes over detrimental functions after 
acute apoptotic stress. In the present model, Omi/HtrA2 appears to act upstream of 
mitochondrial AIF release rather than in downstream caspase-dependent execution 
mechanisms since inhibition of Omi/HtrA2 clearly prevented AIF translocation and 
glutamate-induced neuronal cell death. Most importantly, the Omi/HtrA2 inhibitor 
failed to prevent tBid-induced apoptosis, which puts Omi/HtrA2-mediated apoptosis 
pathways upstream of or independent of Bid. If and how Omi/HtrA2 contributes to 
Bid-mediated AIF release has to be addressed in further studies; data from the 
present study demonstrate that Omi/HtrA2 neither cleaves Bid in a direct manner nor 
accelerates Bid cleavage by caspase-1 or caspase-8. It is also interesting to note, 
that AIF-siRNA and Omi/HtrA2 inhibitor UCF-101 did not show an additional 
protective effect. This suggests that AIF and Omi/HtrA2 are connected to each other 
in their pro-apoptotic function. 
4.2.2 Staurosporine-induced apoptosis is independent of Bid 
The present model of glutamate toxicity in HT-22 neurons features Bid-mediated 
mitochondrial membrane permeabilization and nuclear translocation of AIF, whereas 
activation of Bid and translocation of AIF to the nucleus have not been detected as 
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essential features for STS-induced apoptosis which is consistent with previous 
observations in non-neuronal cells [113, 114]. STS is a low molecular weight inhibitor 
of protein kinases, especially of typical, calcium dependent protein kinase C (PKC). 
Damaging neurons with STS leads to apoptosis on a pathway different from the 
mechanisms after excitotoxic insults and calcium elevation. For example the typical 
apoptotic DNA laddering occurs after STS-treatment while calcium levels stay 
constant. Indeed, high extracellular potassium levels attenuated STS-induced cell 
death by increasing calcium influx through voltage-dependent calcium channels [115, 
116]. Downstream of the PKC-inhibition, treatment of neurons with STS leads to an 
activation of caspase-8 and caspase-3. It is interesting to note that despite an 
activation of caspase-8 and potential subsequent Bid cleavage with mitochondrial 
membrane permeabilization, there was no breakdown of the mitochondrial 
membrane potential shown [117]. In contrast, glutamate-induced excitotoxic 
apoptosis was mediated caspase-8-independent but with a breakdown of the 
mitochondrial membrane potential. This is in line with the present findings in the STS-
damage model of HT-22 neurons: Bid inhibitors could not prevent STS-induced 
apoptosis in HT-22 neurons. Consequently, without a Bid-mediated breakdown of the 
mitochondrial membrane potential, there was no mitochondrial release and nuclear 
translocation of AIF, and AIF siRNA did not protect HT-22 neurons from STS-induced 
apoptosis. In sum these findings show, that apoptosis is a flexible mechanism, 
changing the involved cascades depending from its specific stimuli. Therefore many 
cell death models are needed to further clarify the interrelations between the single 
pro-apoptotic factors upon activation by different initiators of apoptosis. For research 
on mechanisms of neurodegeneration cell damage models involving increased 
intracellular calcium levels and oxidative stress, such as glutamate toxicity, OGD or 
amyloid-β toxicity, are likely more suitable than STS-induced apoptosis which bears 
no reference to a distinct neurological disorder and which was used as an counter-
example to glutamate-induced cell death in the present study. 
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4.3 Activation of Bid 
Since Bid is apparently a key regulator in glutamate-induced neuronal apoptosis 
further experiments focused on the activation of Bid after the glutamate challenge. As 
outlined above, a direct involvement of Omi/HtrA2 in Bid cleavage could be excluded. 
Similar negative results were obtained when addressing other prominent candidates 
that have been linked to Bid cleavage and activation: Caspase-8 and caspase-2 have 
been shown to cleave Bid mediating apoptosis induced by Fas/TNF or TRAIL 
receptor stimuli, respectively [118, 119]. Increases in intracellular calcium levels 
activate Calpain I, which is also suggested to cleave Bid thereby triggering tBid 
mediated mitochondrial damage [120]. In addition, calpain has been identified to 
mediate cleavage and release of AIF from isolated mitochondria, after entering the 
mitochondrial intermembrane space through the tBid-generated pore in the 
mitochondrial outer membrane [75]. The lysosomal involvement in neuronal 
apoptosis triggered by oxidative stress is being increasingly recognized and may 
involve mitochondrial membrane permeabilization either directly through activation of 
phospholipases or indirectly through cleavage of Bid. For example, the lysosomal 
cysteine proteases such as Cathepsin B, D, H and L have been reported to mediate 
Bid cleavage, subsequent activation of Bax by tBid, and mitochondrial release of 
cytochrome c, AIF, and Smac/Diablo [90]. The findings of this work, however, 
strongly suggest that none of these factors that may act upstream of Bid cleavage 
and mitochondrial AIF release are involved in glutamate-induced apoptosis of HT-22 
neurons: Inhibition of caspase-8 or caspase-2, calpains or cathepsins failed to 
prevent glutamate-induced cell death in HT-22 neurons.  
In addition, blocking of p38 MAP kinase, a stress responding cellular serine/threonine 
kinase, did not protect HT-22 neurons exposed to glutamate. For example, in 
Parkinson’s models of cell death, p38 has been shown to be activated, with 
subsequent cleavage of Bid, but these findings apparently had no relevance for 
glutamate-induced cell death of neurons.  
In contrast, the caspase-1 inhibitor (ICE inhibitor II) provided moderate protection 
against glutamate neurotoxicity, confirming previous reports suggesting the 
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involvement of caspase-1 in this model system [21]. Here Bid was confirmed as a 
substrate for caspase-1 in the in vitro assay. In sharp contrast to the pronounced 
protective effects of the Bid inhibitor over a wide range of glutamate concentrations, 
however, inhibition of caspase-1 only provided moderate protection against the 
glutamate challenge and this protective effect was hardly detectable at high 
concentrations of glutamate, i.e. strong apoptotic stress. Therefore, other 
mechanisms are likely involved in Bid activation and the apoptotic signaling in 
addition to the activation of caspase-1. It is interesting to note, that the combination 
of caspase-1 inhibitor and the Omi/HtrA2 inhibitor provided additive protective 
effects. This finding suggests that caspase-1 and Omi/HtrA2 may act in parallel 
pathways of apoptotic signaling towards Bid activation and AIF release after 
glutamate challenge. In addition, Omi/HtrA2 may support the upstream activation of 
caspase-1 by enhanced cleavage of IAPs which may result in an acceleration of 
Caspase activity. In addition, recent data suggested that activation of Bid and 
translocation to the mitochondria does not necessarily require Bid cleavage [81, 82]. 
In particular, a recent study by Prehn and co-workers demonstrated translocation of 
full length Bid to the mitochondria in glutamate-treated cells prior to disruption of the 
mitochondrial membrane potential [81]. Further, phosphorylation of Bid by ATM at 
Serin 61 or Serin 78 has been suggested as a mechanism of activity regulation, e.g. 
in response to DNA damage [71, 72, 90]. On the other hand, phosphorylation of Bid 
by casein kinases I + II at Threonine 58 and / or Serine 61, which are adjacent to the 
caspase-8 cleavage residue Aspartate 59, prevents Bid truncation by caspase-8 and 
has therefore been suggested as a mechanism to control mitochondrial amplification 
of apoptotic signaling [121, 122]. Thus, cleavage of Bid by caspase-1 may be just 
one possible mechanism among others to regulate Bid activity and mitochondrial 
translocation of truncated or full length Bid in glutamate neurotoxicity. These 
mechanisms may involve activation of Omi/HtrA2 or alterations of Bid 
phosphorylation and require further investigation. The following scheme shows 
possible Bid-activation mechanisms for glutamate-induced apoptotic pathways. 
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Figure 44: Bid-activating mechanism in glutamate-treated neurons 
Caspase-1, but not Omi/HtrA2 is able to cleave Bid. After glutamate damage of neurons, Bid is 
activated by caspase-1 and in parallel by Omi/HtrA2which may support the activity of caspase-1. Bid 
or tBid mediate the mitochondrial release of AIF and subsequent cell death. 
 
4.4 Glutamate toxicity in HT-22 neurons is a relevant 
model for neurodegenerative diseases: 
As shown above, glutamate-treatment of HT-22 neurons leads to oxidative stress, 
elevation of intracellular calcium levels and mitochondrial damage. Since oxidative 
stress, increased calcium levels and subsequent trigger of mitochondrial cell death 
pathways are key mechanisms in various models of neuronal cell death, glutamate-
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treatment of HT-22 neurons is a relevant in vitro model for neurodegenerative 
diseases: For example, parallel experiments in primary cultured neurons 
demonstrated pronounced neuroprotective effects of different Bid inhibitors in models 
of glutamate-induced apoptosis or oxygen-glucose deprivation. In both models of 
neuronal cell death, activation of glutamate receptors mediates rapid increase of 
intracellular calcium levels and an excitotoxic death program that involves the 
formation of ROS, permeabilization of the mitochondrial membrane and 
mitochondrial release of AIF [98, 123]. It is therefore concluded that Bid plays a key 
role in neuronal cell death induced by excitotoxic stimuli and oxidative stress which 
both have been associated with a wide variety of neurodegenerative conditions 
following acute brain injury by cerebral ischemia or brain trauma as well as chronic 
neurodegenerative diseases, such as Alzheimer’s disease [124]. It is interesting to 
note that very similar to the presented protection against glutamate toxicity 
pharmacological inhibition of Bid also prevented AIF translocation to the nucleus and 
cell death in HT-22 neurons exposed to amyloid-beta peptide (data not shown). The 
relevance of the current data on the key role for Bid in neuronal cell death in vitro is 
further underlined by recent data obtained in mouse models of cerebral ischemia [65] 
and brain trauma [67]. In both models of acute brain injury, Bid cleavage has been 
detected after the respective insults, and Bid knockout resulted in significant 
cerebroprotective effects compared to wildtype animals. Therefore the presently used 
Bid inhibitors, BI-6C9 and BI-11A7, may emerge as promising lead structures for 
neuroprotective drugs in the treatment of neurodegenerative diseases. These two 
compounds expose different solubility in the different media depending on the serum 
content and were therefore used in serum-containing medium for HT-22 neurons (BI-
6C9) or in serum-free medium for primary neurons (BI-11A7), respectively. The 
effectivity of both these compounds was similar in the respective model system. 
Based on these findings in HT-22 and primary neurons it could be shown that 
glutamate damage of HT-22 neurons is an appropriate model to investigate neuronal 
apoptosis. Since apoptosis for example in Alzheimer’s disease [125], stroke [126] 
and also in models of excitotoxicity in primary neurons (see above) is related to 
oxidative stress, intracellular increase of calcium levels and mitochondrial 
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dysfunction, a scheme universally valid for different models of neurodegenerative 
disorders, could be developed. This involves Bid as a pivotal factor upstream of the 
breakdown of mitochondrial membrane potential and AIF as the leading executor of 
neuronal apoptosis induced by intrinsic mechanisms (Figure 45). 
Figure 45: Proposed mechanism of apoptosis by neurodegeneration based on findings in the 
glutamate-damage model of HT-22 neurons. 
Neurodegeneration induced by ischemia in stroke, glutamate in trauma or Amyloid-beta in 
Alzheimer’s’ disease is followed by an increase of reactive oxygen species and Calcium levels in the 
neurons. This results in cleavage of Bid to tBid, which together with Bax or alone can form pores in the 
mitochondrial outer membrane, breakdown of the mitochondrial membrane potential, and further 
enhanced production of ROS. This vicious circle can lead to the activation of caspases and, most 
importantly, to the release and activation of caspase-independent proteins such as AIF which causes 
DNA damage, nuclear condensation and cell death. Bid inhibitors were able to interrupt the pathway 
upstream of mitochondrial damage. 
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5 Summary 
The Bcl-2 family members play an important role in the control of programmed cell death 
by either promoting or preventing the release of pro-apoptotic mitochondrial proteins. In 
the present thesis the roles of the pro-apoptotic Bcl-2 family member Bid and 
mitochondrial protein AIF were investigated in glutamate-induced neuronal apoptosis. 
After exposure to glutamate, neuronal cell death was determined by MTT assay and 
annexin-V-FITC staining with subsequent FACS analysis in immortalized hippocampal 
mouse neurons (HT-22), or by quantification of apoptotic nuclei by Hoechst staining in 
primary rat neurons. In addition, caspase-3 activity was determined as well as caspase-
independent death signaling, such as mitochondrial release of AIF. Bid-siRNA or 
pharmacological inhibition of Bid rescued HT-22 neurons from glutamate-induced 
apoptosis with similar efficiency. In addition, a small molecule Bid inhibitor significantly 
attenuated the loss of mitochondrial membrane potential, reduced activation of caspase-
3, and prevented AIF translocation to the nucleus in HT-22 neurons exposed to 
glutamate. The specificity of the Bid-inhibitor was demonstrated in tBid overexpression 
experiments. It is interesting to note that AIF-siRNA also attenuated glutamate toxicity in 
HT22 cells whereas the general caspase inhibitor Z-VAD-fmk alone did not exert 
neuroprotection, suggesting that mainly caspase-independent mechanisms executed 
glutamate-induced cell death in this experimental paradigm. In addition, inhibition of 
Omi/HtrA2, which can promote apoptotic death signaling in a caspase-dependent and 
caspase-independent manner, also rescued HT-22 neurons from glutamate-induced 
apoptosis by prevention of AIF translocation. Similar findings were observed in primary 
embryonic rat neurons where Bid inhibitors prevented AIF-translocation and cell death 
after exposure to glutamate. Overall, the data of this thesis reveal that Bid plays a key 
role for the release of pro-apoptotic molecules such as AIF from mitochondria thereby 
promoting caspase-independent cell death. Small molecule inhibitors of Bid may 
therefore emerge as promising therapeutics in neurodegenerative diseases where 
programmed cell death is prominent. In addition it has been shown that glutamate 
damage of HT-22 neurons is an appropriate model for apoptotic cell death induced by 
glutamate, relevant to mechanisms that occur in many neurodegenerative diseases. 
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6 Appendix 
6.1 Abbreviations 
A Ampere 
AIF apoptosis inducing factor 
AMPA alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
Apaf-1 apoptosis protease-activating factor-1 
APS ammonium persulfate 
ATM ataxia telangiectasia mutated 
ATP adenosine triphosphate 
Bcl-2 B-cell lymphoma-2 
bp base pairs 
CAD caspase-activated deoxyribonuclease 
CARD caspase recruitment domain  
CCCP carbonyl cyanide m-chlorophenylhydrazone 
cDNA copy DNA 
CHAPS 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate 
CO2 carbon dioxide 
DAPI 4’, 6-diamidino-2-phenylindole dihydrochloride  
dATP deoxy Adenosine triphosphate 
dCTP deoxy cytosine triphosphate 
DD death domain 
DED death effector domain 
dGTP deoxy guanosine triphosphate 
DMEM  Dulbecco’s modified Eagle medium 
DMSO dimethyl sulfoxide 
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DNA deoxyribonucleic acid 
dNTP  deoxy nucleotide triphosphate 
dsRNA double-stranded RNA 
DTT D,L-dithiotreitol 
dTTP deoxy thymidine triphosphate 
EBSS Earle’s balanced salt solution 
EDTA ethylenediaminetetraacetic acid disodium salt 
EGFP enhanced green fluorescent protein 
EGTA ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic 
acid 
ER endoplasmatic reticulum 
FAD flavin adenine dinucleotide 
FasL Fas ligand 
FCS fetal calf serum 
FENS Federation of European Neurosciences 
FITC fluorescein isothiocyanate 
g relative centrifugal force 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 
GFP green fluorescent protein (=EGFP) 
h hour(s) 
HBSS Hanks’ balanced salt solution 
HEPES 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
Hq harlequin 
HRP horse reddish peroxidase 
IAP inhibitor of apoptosis 
ICAD inhibitor of caspase-activated deoxyribonuclease 
ICE interleukin converting enzyme (caspase-1) 
IgG immunoglobulin G 
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IP3 inositol triphosphate 
JC-1 5,5',6,6'-tetrachloro-1,1',3,3'-
tetraethylbenzimidazolylcarbocyanine iodide 
kb kilo base 
KCl potassium chloride 
LiCl lithium chloride 
mAIF_pd2EGFP-N1 plasmid encoding for a AIF, coupled to EGFP under control of 
the CMV promoter/enhancer 
MAPK mitogen activated protein kinase 
MEM Eagle’s minimum essential medium 
MgCl2 magnesium chloride 
Min minute(s) 
MLS mitochondrial localization sequence 
MTT 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
NA numeric aperture 
NaHCO3 sodium hydrogen carbonate 
NaOH sodium hydroxide 
NB neurobasal medium 
NB+ neurobasal medium plus B27 supplement 
NLS nuclear localization sequence 
NMDA N-methyl-D-aspartate 
OGD oxygen glucose deprivation 
Omi/HtrA2 high temperature requirement protein A2 
p.a. pro analysi 
Parg poly(ADP-ribose) glycohydrolase 
PARP poly(ADP-ribose) polymerase 
PBS phosphate-buffered saline 
pcDNA 3.1+  empty plasmid with a CMV promoter/enhancer 
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PCR polymerase chain reaction 
pd2pEGFP-N1  plasmid encoding for EGFP under control of the CMV 
promoter/enhancer 
pDsRed2-Bid  plasmid encoding for a fusion protein of red fluorescent 
protein and Bid under control of the CMV promoter/enhancer 
pEGFP-Luc plasmid encoding for EGFP and Luciferase under control of 
the CMV promoter/enhancer 
pEGFP-N1 plasmid encoding for EGFP under control of the CMV 
promoter/enhancer 
PFA paraformaldehyde 
pgWIZ-GFP plasmid encoding for EGFP under control of the CMV 
promoter/enhancer 
pH potentia hydrogenii 
PI propidium iodide 
poly-hema polyhydroxyethylmethacrylate 
PVDV polyvinylidenfluorid 
RIP 2 receptor interacting protein 2 
RNA ribonucleic acid 
ROCK Rho-associated kinase 
ROS reactive oxygen species  
RT room temperature 
RT-PCR reverse transcription polymerase chain reaction 
SD standard deviation 
SDS sodium dodecyl sulfate 
siRNA small interfering ribonucleic acid 
Smac/Diablo second mitochondrial derived activator of caspase 
SOD superoxide dismutase 
STS staurosporine 
TBE buffer containing Tris, boric acid and EDTA 
tBid truncated Bid 
TBST Tris-buffered saline with Tween 20 
6 Appendix  93 
TE PBS containing 0.05% trypsin and 0.02% EDTA 
TEMED N,N,N',N'-tetramethylethylenediamine  
TNF tumor necrosis factor 
Tris Tris(hydroxymethyl)aminomethane 
U unit(s) 
UV ultraviolet 
V Volt 
XIAP X-chromosomal linked inhibitors of apoptosis 
6.2 Publications 
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and focal cerebral ischemia. Journal of Neuroscience, 25:10262-10272. 
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